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 The brain controls many functions including memory, learning, and addiction. Being able 
to measure neurochemical changes associated with these processes can elucidate and provide 
insight into the neural mechanisms that are responsible for each function. The main technique 
used to sample from the central nervous system is microdialysis. Active tissue processes can 
affect the recovery of microdialysis probes which can be problematic when quantifying absolute 
neurotransmitter concentrations. 
 In this work, we develop a novel approach to calibrating microdialysis probes in vivo 
based on infusing stable-isotope labeled (SIL) neurotransmitters and measuring loss of SIL 
standard. This allows transport across the membrane and probe recovery to be calculated 
enabling quantitative measurements. Additionally, the use infusion of SIL compounds allows 
flux and metabolism of these neurotransmitters by different pathways to be monitored by 
measuring downstream metabolites. 
Quantitative microdialysis is performed on dopamine (DA), glutamate (Glu), and the 




C5-Glu through the 
probe, the extraction fraction and the apparent concentration (Capp) were shown to equal that of 
no-net-flux (NNF), an established but slower quantitative microdialysis technique. This SIL 
microdialysis method is also demonstrated to be applicable under transient conditions unlike 
NNF. 
 This new microdialysis technique was used to measure the effect of acute leptin on DA in 
the nucleus accumbens of rats.  in the nucleus accumbens decreased by 30 ± 5% after an
ix 
 
injection of leptin but did not decrease after a vehicle injection. The cause of this decrease was 
further investigated by administering raclopride, a D2 antagonist, to rats that received vehicle or 
leptin. These experiments provide evidence that leptin increases uptake. 





C5-Gln. Glu is preferentially formed from Gln in the neuron so the 
13
C5-Glu produced should be neuronally derived. Administration of tetrodotoxin and 
metabotropic glutamate receptors decreased the 
13
C5-Glu by 60 ± 7% and 56 ± 10%, respectively. 
An increase in 
13
C5-Glu was detected when a stressor (tail pinch) was applied to the animal. 
These tests indicate that the 
13






Measuring neurochemicals in the central nervous system can give insight into the 
mechanisms of cognition, mental disorders, addictions, and many other mental processes. 
Studies based on such measurements can be important in developing cures, preventative 
measures, and therapeutics for various diseases and addictions. A common approach in early 
studies on CNS neurochemistry was to remove the brain and measure tissue content of chemicals 
or prepare slices for monitoring chemical release ex vivo.
1-3
 While useful, these studies are 
limited. The interactions of brain circuits cannot be accounted for and behavioral correlation with 
neurochemistry is not possible. Techniques have since been developed to measure chemicals 
from the brains of conscious, intact animals. These analytical methods provide additional 
information to brain slice studies that were previously performed. Achieving such measurements 
requires high spatial and temporal resolution, sensitivity, and selectivity.  
Neurotransmission overview 
Neurons, which consist of dendrites, a cell body, and an axon, are the primary 
information units of the central nervous system. Communication between neurons is performed 
mainly through chemicals called neurotransmitters. Neurotransmitters can be small molecules, 
such as glutamate (Glu) and dopamine (DA), or larger neuropeptides, such as enkephalins. 
Axons from one neuron and juxtaposed cells (neuronal, muscular, or glandular) form synapses 
that enable chemical or electrical communication. The space between neurons in a synapse is the 
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Figure 1.1: Overview of neuroanatomy (A) Neurons 
consist of dendrites, cell bodies, and axons. (B) 
Released neurotransmitters can be enzymatically 
degraded, activate receptors, get transported into the 
neuron or glia, or can diffuse out into the extracellular 
space. Reprinted from Schultz, K. N.; Kennedy, R. T. 
Annual Review in Analytical Chemistry 2008, 1, 627-
661. 
synaptic cleft (~100 nm wide). Once released into the synaptic cleft, neurotransmitters can bind 
and activate receptors in the synapse on either pre- or post-synaptic neurons. Neurotransmitter 
molecules may also diffuse away from the synaptic cleft contributing to “overflow” or spill over 
where they may activate receptors more distal to the synapse. To terminate the signal, 
neurotransmitters may be taken into the 
intracellular space via transporter 
proteins or degraded by enzymes. (Fig. 
1.1)  
In classical neurotransmission, 
the neuron is held at a resting potential 
of -70 mV with a sodium-potassium 
pump. Dendrites gather excitatory or 
inhibitory signals on the membrane 
from neurotransmitters activating 
receptors on the dendrites. If the sum of 
the inputs collected by the dendrites 
causes the membrane to reach a 
threshold potential of around -55 mV, 
an action potential is initiated. The 
action potential propagates down the axon to the axon terminal. When the action potential 
reaches the axon terminal, voltage-gated Ca
2+
 channels open. The influx of Ca
2+
 causes vesicles 






The communication between neurons is mediated by gap junctions and, more commonly, 
activation of receptors by neurotransmitters. Many different types of receptors are located on 
distinct areas of both neurons and astrocytes. In this thesis, DA and Glu receptors will be 
discussed. Five different DA receptors have been identified and designated D1-5. D1 and D5 
receptors share similar structures in their trans-membrane domains and are classified as D1-like 
family. These receptors activate adenylyl cyclase. Activating D1 receptors has been shown to be 
involved in reward seeking behavior. For example, administering a D1 agonist systemically 
decreased the reinstatement of drug seeking behavior following a cocaine prime.
4
 D2, D3, and D4 
receptors belong to the D2-like family which, when activated, inhibit the formation of cAMP by 
inhibiting the enzyme adenylyl cyclase.
5
 D2 receptors are located on the presynaptic and post-
synaptic neuron. The presynaptic D2 receptor acts in a modulator function, affecting synthesis, 
storage, and release of DA through feedback mechanisms.
6
 The post-synaptic D2 receptor 
transmits inhibitory or excitatory signal to the neuron. Because D2 receptors can act as 
modulators of DA, blocking D2 receptors can stop the negative feedback of presynaptic neurons 
caused by extracellular DA.
7-10
 This mechanism is exemplified in multiple studies including one 
where raclopride (1.2 mg/kg, i.p.), a D2 antagonist, was administered to a rat while DA was 




Two classes of Glu receptors have been identified, ionic Glu receptors, which mediates 
fast synaptic transmission, and metabotropic Glu receptors (mGluR), which couple to G-proteins 
and are responsible for modulating slow synaptic transmission.
8, 9
 The different types of 
ionotropic glutamate receptors are 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
(AMPA), kainite, and N-methyl-D-aspartate (NMDA) receptors.
8
 When Glu binds to these 
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 can cross the membrane which can induce an 
excitatory postsynaptic current. 3 groups of mGluRs have been discovered: group I, group II, and 
group III. In rat hippocampus slices, group II and group III mGluRs were shown to be localized 
mainly to the presynaptic neuron, while group I was located in the postsynaptic neuron.
10
 Group 
II mGluRs appear to act as autoreceptors, decreasing Glu release in synaptosomes and 
electrically stimulated Glu release in the striatum of rats when activated.
11, 12
 
Importance of measuring Glu in the central nervous system 
Glu is the main excitatory neurotransmitter found in the brain. Several disorders can arise 
when Glu is not regulated correctly. Thus, measuring extracellular Glu can provide information 
on the cause of these disorders and how to better treat them. For example, an excess of Glu in the 
medial prefrontal cortex has been linked with schizophrenia
13-15
 and an excess of Glu in the 
hippocampus has been associated with epilepsy.
13, 16
 Administering a group II mGluR agonist 
(lowers extracellular Glu concentrations in brain) reduced seizures in epileptic models of mice
17
 
and decreased schizophrenic symptoms in humans.
18
  
Glu has also been shown to be an integral part in drug seeking behavior. In a previous 
study, rats were allowed to press a lever to self administer cocaine daily for 5 days. The reward 
seeking behavior was then extinguished by substituting saline for cocaine. Rats then had a DA 
receptor antagonist (fluphenazine) or an AMPA receptor antagonist (decreases extracellular Glu) 
microinjected into the NAc prior to a systemic injection of cocaine. Rats that received the DA 
receptor antagonist produced the same lever presses as before, while rats that received AMPA 
receptor antagonist had a reduction in lever presses.
19
 This study showed that Glu, and not DA, 
was responsible for the reinstatement behavior.  
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Figure 1.2: Metabolic pathway of dopamine in the brain. DA can be 
taken up into the neuron with DAT and metabolized to DOPAC 
through MAO. DOPAC can be further metabolized to HVA via 
COMT. DA that isn’t taken up can be converted to 3-MT via COMT, 
which can be further metabolized to HVA. 
These studies relied on measuring Glu dependent behavioral changes and Glu 
concentrations in tissue slices. Measuring Glu in an intact, conscious animal can lead to better 
therapeutics for diseases like schizophrenia, epilepsy, and addiction. Analytical techniques 
capable of making these measurements are necessary to gain further understanding of the role of 
Glu in the brain. 
Like Glu, DA is associated with addiction and schizophrenia, along with a number of 
other functions. DA is considered to be the main “reward” neurotransmitter in the brain. 
Understanding how it is regulated can aid in interpreting extracellular DA measurements and can 
provide insight into incentive salience, reward seeking behavior, and therapies for diseases such 
as Parkinson’s disease.  
Role of DA in the central nervous system 
 DA is regulated 
differently than Glu. In 
addition to point-to-point 
communication between 
dopaminergic neurons, DA 
synapses can be more 
“open” compared to Glu 
synapses in that they rely 
on diffusing to 




Once released from a neuron, DA can reach different metabolic fates. It can get taken up by the 
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neuron via the DA active transporter (DAT) where it can be repackaged in vesicles for release 
later, or be metabolized into 3,4-dihydroxyphenylacetic acid (DOPAC) via the monoamine 
oxidase (MAO) enzyme (Fig. 1.2). DOPAC can be further metabolized to homovanillic acid via 
catechol-O-methyltransferase (COMT). DA that is not taken up into the neuron can be 
metabolized to 3-methoxytyramine (3-MT) by COMT in the extracellular space. 3-MT can be 
metabolized to HVA via MAO. 
Dopaminergic neurons are found in, but not limited to, the midbrain, hypothalamus, and 
olfactory bulb.
21
 Multiple diseases arise when DA is not regulated correctly, including a lack of 
DA in the striatum causes Parkinson’s disease. Symptoms can be alleviated with L-DOPA 
(precursor to DA) treatments.
22
 One cause of schizophrenia is believed to be over activation of 
DA receptors. Antipsychotics, which block D2 receptors, are the most common treatment for 
schizophrenia. 
DA is also associated with addiction and reward seeking behavior. In a review by 
Robinson and Berridge, the authors hypothesize that DA in brain regions associated with drug 
“wanting” are responsible for addiction. Sensitization of the mesotelencephalic DA system, 
associated with “wanting,” caused by repeated drug use increases the incentive salience of 
stimuli associated with the drug.
23
 As a consequence of sensitization, normal "wanting" can 
become compulsive drug craving. 
Multiple studies have provided evidence that this theory is correct. For example, in one 
report rats were given 4 daily injections of amphetamine (increases DA in the mesotelencephalic 
system) or saline. Amphetamine was then given to both groups on day 5. The amphetamine 
treated rats showed greater behavioral sensitization compared to saline treated rats. When the rats 
were allowed to self-administer amphetamine following daily injections, the rats that received 
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amphetamine self-administered more than the saline treated rats.
24
 This supports the theory 
because sensitization elicited greater self administration. All rats had been exposed to the 
amphetamine but the sensitized rats “craved” the drug more. 
In addition to drug addiction, DA is also important in feeding behavior. Transgenic mice 
that cannot produce DA exhibited low locomotor activity and did not feed. These mice usually 
died within a few weeks. When given chronic injections of L-DOPA, the mice exhibited 
behavior close to wild-type mice.
25
 In a separate study, increasing DA in the NAc of rats by 
microinjecting of amphetamine into the NAc increased the incentive salience of sucrose.
26
 
Although DA is important for feeding, it is not the only factor. Feeding is a complex behavior 
and understanding the interactions that DA plays with other neurotransmitters, neuropeptides, 
and hormones, may help provide information to why feeding can become irregular (e.g. anorexia 
and obesity). 
Leptin affects DA and reward circuitry 
 One hormone that may be involved in regulating  DA signaling is leptin. Leptin has 
generated interest due to the profound effects of the absence of leptin or leptin receptors on 
feeding behavior. Leptin deficient mice (ob/ob) exhibited obesity and low energy expenditure.
27
 
The same is true with leptin receptor deficient mice (db/db).
28, 29
 When treated with leptin, ob/ob 
mice exhibited phenotypes closer to wild-type mice, but db/db mice did not.
30, 31
 In humans, 
people born with congenital leptin deficiencies tend to be overweight. Chronic treatment with 
leptin increased energy output and reduced body fat in a human with this leptin deficiency.
32
 
Studying where leptin receptors are located and how these areas affect feeding can lead to a 
better understanding of obesity. 
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 Leptin receptors have been found in multiple brain areas, including the lateral 
hypothalamus (LH), ventral tegmental area (VTA), and brain stem.
33-35
 Using patch-clamp 
electrophysiological measurements, leptin was shown to depolarize 34% of leptin receptor 
containing neurons in the LH area.
36
 Fluorescent tagging of neurons with leptin receptors in the 
LH revealed that these neurons innervated the VTA, but did not innervate the NAc.
34, 36
 
Although no leptin receptor containing neurons from the LH area innervate the NAc, neurons in 
the VTA, which are affected by leptin, have been demonstrated to innervate the NAc.
37
 These 
brain areas are often associated with reward and reinforcement.
23, 38
 Measuring how leptin affects 
DA in these areas may provide insight into how leptin alters feeding behavior. In this 
dissertation, we use novel techniques to further study how leptin interacts with the DA system as 
discussed in chapter 3. 
Understanding how neurotransmitters like DA and Glu affect feeding, addiction, disease, 
and cognition can provide insight into cures, preventative measures, and a more general 
understanding of the brain. Behavioral measurements alone yield a limited amount of 
information; however, being able to quantify these neurochemical changes in intact brains is 
hampered by large challenges and methodological requirements. 
Challenges in measuring neurochemicals 
One challenge with measuring neurochemicals in rodents is the physical size of the 
brains. Further, the brain is a heterogeneous structure with discrete regions. Neurochemical 
events can occur in specific areas that can be 0.5 mm
3 
or smaller. Therefore, the spatial 
resolution of the sensor or probe used has to be adequate for measuring from the area of interest 
exclusively without interference from other brain structures.  
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Figure 1.3: Importance of high temporal resolution 
measurements. When presented with a fox odor, 10 min 
fraction collection showed a long, slow increase in Glu 
(open triangle). When measured with 14 s temporal 
resolution (open circle), there is a biphasic response of Glu. 
If the 14 s data is binned (filled circle), the data looks 
similar to the 10 min fraction collection. Some animals 
labeled high responders (black line) showed an even 
greater increase in Glu. Reprinted with permission from 
Venton, B. J.; Robinson, T. E.; Kennedy, R. T. J. 
Neurochem. 2006, 96, 236-246. 
In addition to using small 
probes, neurotransmitters should be 
measured with a high temporal 
resolution. Neurochemical events 
can occur on the ms timescale (e.g. 
exocytosis) up to the month 
timescale (e.g. addiction). In order to 
gain as much information as 
possible, making measurements at 
high temporal resolutions can 
measure changes that would 
otherwise be unseen with slower 
measurements. For example, when a 
fox odor was presented to rats, a 
long, slow increase in Glu was 
detected when measured with a 10 min temporal resolution (Fig. 1.3).
39
 With a 14 s temporal 




Sensitivity is also an issue when measuring from the brain. Neurotransmitter 
concentrations range from pM to mM. The detection method must be sensitive in order to 
measure the analyte of interest. Finally, high selectivity is required. The brain consists of, but is 
not limited to, tissue, blood, proteins, enzymes, and neurotransmitters. Being able to differentiate 
10 
 
select neurotransmitters from other chemicals in the brain is necessary for performing accurate 
measurements. 
A problem specific to Glu measurements is the pool of extracellular Glu in the ECS can 




. Glu is highly regulated in the brain due to 
its neurotoxicity at higher concentrations.
46, 47
 To prevent neurotoxic Glu concentrations, 
astrocytes rapidly clear Glu via excitatory amino-acid transporters (EAATs) and convert the Glu 
to glutamine (Gln).
48-50
 A technique that can measure Glu derived specifically from the neuronal 
pool is required to better understand diseases and addictions caused by abnormalities in neuronal 
Glu regulation. 
Being able to distinguish the neurotransmitter of interest from the other chemicals in the 
brain with high sensitivity is crucial for accurate measurements. Several methods have been 
developed that attempt to meet these criteria. These methods include both non-sampling and 
sampling techniques. 
Non-sampling methods for measuring DA 
One approach to studying DA in the brain is positron emission tomography (PET). In 
PET, radiotracers are injected into the subject. The emission of γ rays from the radioactive decay 
of the radiotracer are monitored.
51, 52
 The largest advantage with PET is that it is non-invasive. 
Although DA cannot be directly measured with PET, dopaminergic receptor activity can 
be monitored. For example, the concentration of extracellular DA in the brain can be correlated 
to the binding of 
11
C-raclopride (D2 antagonist) to D2 receptors. This method was used to 
demonstrate that patients with schizophrenia had a greater decrease in 
11
C-raclopride binding 





raclopride binding decreased more in schizophrenic patients, then more DA must have been 
11 
 
released. The extra DA occupies more D2 receptors and less 
11
C-raclopride is able to bind to 
them. 
Although a non-invasive approach seems ideal for measuring neurochemical events, PET 
has many disadvantages. Currently, the radiotracers available are limited. This translates to a low 
amount of neurochemical systems, namely DA and serotonin (5-HT)
54
, that can be measured 
with PET. Secondly, the spatial resolution is low. Typical human PET scanners have spatial 




 While acceptable for studies on larger subjections, it is problematic 
for small rodents. Additionally, PET requires the head to remain still, so PET on rodents is 
typically done under anesthesia, which precludes correlation with behavior. Further, the 
anesthesia can affect neurochemistry and receptor-ligand interactions.
55
 It should be noted that 
recent advances have been made in PET technology that are overcoming these limitations. For 
example, a small, portable PET detector (named RatCAP) has been developed that allows PET 
scanning of awake, conscious rats.
56
 The RatCAP is fixed on the head of the rat and has a 
counterweight to allow the rat to freely move. Measurements that require higher spatial or 
temporal resolution often rely on other techniques, such as electrochemical detection (ECD). 
ECD is a highly sensitive approach that can be performed on short timescales. DA and 
other catecholamines are electrochemically active and thus good targets for electrochemical 
detection. The oxidation of DA to dopamine-o-quinone occurs at about 0.6 V and is reduced 
back to DA at -0.2 V vs. Ag/AgCl electrode.
57, 58
 
Using ECD to measure changes in the brain was pioneered in the 1970s.
59
 Efforts have 
since been made to increase the sensitivity and selectivity of electrochemical detectors.
60, 61
 
Perhaps the most sensitive detection method with the highest temporal resolution and high 
spatial resolution is fast-scan cyclic voltammetry (FSCV). In traditional FSCV, voltage is 
12 
 
Figure 1.4: Overview of fast-scan cyclic voltammetry. Traditional FSCV 
is held at -0.4 V, is increased to +1.0 V, and decreased to -0.4 V in 9 ms. 
This oxidizes dopamine to dopamine-o-quinone and reduces it back to 
dopamine. The signal from the dopamine is subtracted from the 
background current and produces a signature cyclic voltammogram. 
Reprinted with permission from Robinson, D. L.; Hermans, A.; Seipel, A. 
T.; Wightman, R. M. Chem. Rev. 2008, 108, 2554-2584. Copyright 2008 
American Chemical Society. 
 
increased linearly 
from -0.4 to 1.0 V and 
back to -0.4 V across 
a carbon-fiber 
microelectrode in a 
total of 9.3 ms (Fig. 
1.4). Each voltage is 
ramp performed 100 
ms apart. This high 
scan rate produces a 
large charging 
background current. 
The current measured 
from DA is subtracted 
from the background current to provide the signature DA cyclic voltammogram.
62
 With FSCV, 
measuring fast neurochemical events such as exocytosis is possible. 
FSCV has provided great insight into the neuronal DA system, particularly the reward 
circuitry of the brain. As an example of the power of FSCV, a previous study demonstrated the 
effect of DA release during the anticipation and administration of a cocaine injection. This effect 
was demonstrated by conditioning rats to activate a lever to self-administer cocaine. During these 
lever presses, DA was measured via FSCV. The authors detected a small increase in DA in the 
NAc 7.7 ± 0.6 s prior to pressing the lever and receiving cocaine. After the cocaine injection, DA 
increased even more, producing a 2 phase release of DA.
63
 Additionally, when the cocaine and 
13 
 
lever press were associated with an audio-visual cue, DA increased at the presentation of the 
audio-visual cue without the injection of cocaine. Being able to measure DA release with 
behavior in this way has provided great information into mechanisms of drugs of abuse. While 
fast and sensitive, FSCV has a number of disadvantages associated with it. The selectivity of this 
method is problematic. Interferents, such as ascorbic acid (AA), norepinephrine (NE), DOPAC, 
and 5-HT, can obscure the signal produced by DA.
64, 65
 To overcome this limitation, FSCV 
electrodes are placed in brain areas thought to have low concentrations of these interferents, such 
as the NAc.
66
 Measured via other methods mentioned later, the concentration of each of these 
interferents may not be nominal.
67, 68
 
Due to multiple interferents and a large charging background, basal concentrations of DA 
are difficult to obtain with FSCV. Slower electrochemical techniques have estimated basal DA 
concentrations to be 26 nM.
69
 With the use of FSCV, basal DA concentrations have been 
estimated to range between 6 nM
70
 to 2.5 µM.
71
 Recently, a new approach that averaged DA 
transients (subsecond fluctuations in DA levels) with FSCV estimated basal DA concentrations 
to be around 20 nM.
72
 These problems with basal concentrations make FSCV an attractive 
method for measuring differential concentrations, but not absolute differences. 
A third problem with FSCV is the inability to measure DA over long periods of time. 
With problems like electrode fouling and reference electrode drifting, measurements are 
restricted to about 90 s windows.
72-75
 While excellent for measuring short chemical events, these 
limitations are prohibitive when measuring slow changes over longer periods of time. 
FSCV is also limited to measuring mainly DA; however, recent advances have allowed 
FSCV to become more robust. With modified waveforms, FSCV can measure other 




 Coating the electrodes with substances such 
14 
 
as Nafion can also be useful in excluding anions from reaching the electrode. Nafion coating has 




Non-sampling methods for measuring Glu 
Like DA,  electrochemical methods can be used for measuring Glu, which is not natively 
electroactive. To overcome this limitation, electrodes can be coated with L-glutamate oxidase 
(Glu-Ox).
78
 The Glu-Ox produces H2O2 which can be detected at the electrode. These probes 
sometimes have another electrode void of Glu-Ox called the sentinel electrode.
41
 In these probes, 
the signal produced from the enzyme coated electrode is subtracted from the signal of the 
sentinel. 
These electrodes have been used in several proof-of-concept studies for Glu 
measurements. The effect of a stressor (tail pinch) on Glu was measured in the striatum and the 
prefrontal cortex of rats.
79-81
 After the tail pinch, Glu increased about 170% basal. These 
electrodes have shown impressive temporal resolution, which allows Glu transients to be 
measured. Glu transients were shown to increase in the basolateral amygdala (an area associated 
with reward seeking behavior) when rats were presented with a food reward after pressing a 
lever.
82
 Additionally, Glu sensors can measure TTX induced decreases in extracellular Glu 
concentrations. Local application of TTX in the PFC decreased Glu concentration by ~40%.
80
 
These studies show the ability of Glu sensors to measure fast Glu events that are neuronally 
derived; however, a number of limitations are associated with these electrodes. 
One disadvantage is the ability to only measure 1 neurotransmitter. Measuring multiple 
analytes can lead to discovering the involvement of unanticipated neurotransmitter systems. 
Additionally, although the sentinel electrode can help with removing signal from interferents, it 
15 
 
is still possible that electroactive species can cause artificial signals in the electrodes. For 
example, H2O2 found in the brain can be an interferent.
83
 Ascorbic acid has also been shown to 
decrease the electrode sensitivity by as much as 50%.
83
 Lastly, Glu-Ox is an enzyme, and like all 
enzymes has different relative activities in different conditions, such as pH.
84
 The current design 
of these microelectrodes cannot account for changes in enzyme activity in biological matrices. 
Like the electrodes used to measure DA, controversies arise when comparing basal Glu 
measurements made by sensors to other techniques. Glu biosensors estimate extracellular Glu 
concentrations to be in the low µM levels.
41, 79
 In hippocampal brain slices, basal Glu 
concentrations were estimated to be in the low nanomolar range (~25 nM).
85, 86
 These 
concentrations were estimated by measuring NMDA receptor currents. The discrepancies 
between biosensor and brain slices may be due to the damage each of the methods cause, 
differences in chemical makeup of the brain vs. a perfused buffer, or the presence of different 
compartments of Glu. In the latter case, each method may be measuring from different 
compartments.
87
 Because of the multiple sources of Glu, the highly regulated system of Glu 
clearance, and the limitations of measuring techniques, quantifying Glu in the brain is difficult. 
All of the non-sampling methods discussed above can measure only 1 to 2 analytes at a 
time. Additionally, these methods have difficulty measuring absolute concentrations. To gain 
complementary information about the central nervous system, sampling methods that do not 
have these limitations can be used to obtain a more complete picture of the brain. 
Sampling methods for measuring DA and Glu 
 The main sampling technique for measuring DA and Glu is microdialysis. Microdialysis 
probes have a semi-permeable membrane which allows chemicals to diffuse down a 
concentration gradient in or out of the probe.
88
 The semi-permeable membrane has a cutoff 
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Figure 1.5: Sampling methods overview. (A) In a 
push-pull probe, 2 side-by-side capillaries are glued 
together. The flow in the flow rates range from 20 nL/min 
to 10 µL/min. (B) Microdialysis probes are made by an 
inlet and outlet capillary ensheathed by a semipermeable 
membrane. The diagram above illustrates a side-by-side 
microdialysis configuration. The ends of the membrane 
are filled with an epoxy or glue. 
weight usually between 20-100 kD
89
. At the lower molecular weight cutoffs, small molecules 
can diffuse across the membrane while larger proteins cannot (refer to Fig. 1.5).  
The relative recovery (RR) of microdialysis is the fraction of analyte that enters the probe 
relative to the external concentration, which is dependent on the flow rate and size of the probe. 
Artificial cerebral spinal fluid (aCSF) 
is perfused through microdialysis 
probes at flow rates ranging from 0.2 
to 5 µL/min. The lower the flow rate, 
the higher the RR and the lower the 
absolute recovery (Fig. 1.6). RR is 
also affected by the active area of a 
microdialysis probe. Smaller active 
areas will recover lower 
concentrations. 
 Although not as popular as 
microdialysis, a second sampling 
technique for monitoring 
neurochemical changes is push-pull 
perfusion (PPP). This method 
involves directly extracting liquid 
from the brain via a vacuum or in-line pump.
90
 aCSF is also pumped in an adjacent fluid line to 
counteract changes in volume associated with removing fluid (Fig. 5). Conventional PPP uses 
flow rates of ~10 µL.
90, 91




Figure 1.6. Recovery is dependent on flow rate in microdialysis. 
Decreasing the flow rate increases the relative recovery of the probe but 
decreases the absolute recovery. The opposite is true when increasing the 
flow rate. 
tissue damage. More recently, low-flow (20-50 nL/min) PPP has been implemented to reduce 
tissue damage.
92, 93
 The surface area of a push-pull probe made of 2 side-by-side 40/100 
(i.d./o.d.) µm capillaries is roughly 200 fold lower than a 2 mm x 200 µM dialysis membrane.94 
While low-flow PPP seems attractive, microdialysis dominates the sampling methods for 
neurochemistry studies due to decreased complexity and greater commercial availability of 
microdialysis probes. Further discussion on sampling method will be focused on microdialysis.  
With microdialysis, collected samples need to be analyzed by a method capable of 
measuring the neurotransmitters of interest. These analyses can either be performed offline or 
online. 
Offline analysis for microdialysis 
The most common method for offline analysis for the detection of DA, Glu, and their 
metabolites is HPLC coupled with fluorescence, electrochemical, or mass spectrometeric 



















. These fluorescent tags react with primary amines which are found on both DA and 
Glu. While fluorescence is a good candidate to measure Glu, measuring DA via fluorescence can 
be difficult due to the low concentration of DA in the brain. Other disadvantages include the 
derivatization time required for a fluorescent tags. Some tags require reaction times of a couple 
min. When looking for high throughput analysis, this derivatization time can be prohibitive. 
Additionally, stability
101
 of the derivatized product and photobleaching
102
 can be problematic. 
When higher sensitivity or stability is required, other detection methods such as ECD may be 
more suitable than fluorescence. 
 HPLC coupled to ECD has been mainly used for measuring electroactive 
neurotrasnmitters such as DA, its metabolites, 5-HT, and NE.
103
 HPLC-ECD can also be used to 
measure Glu. Because Glu is not electrochemically active, derivatization is required. Glu is 
commonly derivatized with OPA to make it electroactive.
104, 105
 While derivatization allows 
more neurotransmitters to be detected, the stability and derivatization times of OPA can be 
problematic with HPLC. The tradeoff between measuring limited electroactive compounds or 
measuring a greater number of derivatized compounds with decreased stability makes HPLC-
ECD an inefficient system. Mass spectrometers (MS), on the other hand, have the potential to 
detect a broad number of analytes with high sensitivity. HPLC-MS has recently gained 
popularity as a method for detecting neurotransmitters in dialysate.
106, 107
 Dialysate can be 
problematic in ESI sources due to the high salt content and the high degree of polarity of most 
neurotransmitters. By derivatizing dialysis samples with a non-polar derivatizing agent, polar 
neurotransmitters are amenable to reversed phase HPLC. The work in this dissertation uses 
benzoyl chloride (BzCl) to enhance separation and detection on an HPLC-MS/MS system. With 
this assay, DA, DOPAC, 3-MT, HVA, Glu, Gln, and 11 other compounds can be measured from 
19 
 
a single dialysis sample.
68
 The limits of detection for this method were measured to be on the nM 
scale.
68
 The low limit of detection combined with the large number of neurotransmitters that can 
be detected in each sample allow monitoring of multiple systems in the brain simultaneously. 
Additionally, stable-isotope labeled (SIL) neurotransmitters can be differentiated from the 
endogenous species with MS analysis. Measuring SIL neurotransmitters can lead to information 
on metabolism and quantification of endogenous neurotransmitters. 
Although HPLC is a robust and comprehensive separation method, several drawbacks 
exist.. One large disadvantage is the time required per separation, which is typically several min. 
A less popular but faster separation method used for offline analysis is capillary electrophoresis 
(CE).
108, 109
 CE separates molecules based on size and charge in an applied electric field. The 
ions move in the direction of electroosmotic flow. Small, positive ions elute out first, followed 
by large positive ions, neutral molecules, large negative ions, and then small negative ions. The 
methods of detection for CE are the same as HPLC, the most common being fluorescence. 
Offline analysis has the advantage of being able to collect samples from multiple animals 
at the same time, which allows for high-throughput analysis. A large disadvantage of offline 
analysis is the inability to make measurements with high temporal resolution. The number of 
samples collected increases exponentially with decreasing collection times. When high temporal 
resolution is required, online analysis is a better suited method. 
Online analysis of microdialysis 





 or enzymatic assay.
93
 Direct infusion of dialysate into an ESI-MS 
has been used to measure acetylcholine (a neurotransmitter)
110
 and enkephalins 
(neuropeptides).
113
 The temporal resolution for direct infusion into an ESI-MS has been 
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measured to be as low as 5 s.
110
 This system utilized segmented flow with droplet sizes of 160 
nL. The low sample size allows for the high temporal resolution which is hard to achieve with 
offline analysis which usually require samples on the µL scale. A main drawback is that the high 
salt content of microdialysis samples can be problematic for ESI. Another limitation is that the 
cost of an MS can be prohibitive, although commercial availability of cost efficient systems is 
increasing. Lastly, the analytes measured with the MS have to be ionized easily. 
Another technique used for online analysis is fast CE. This separation technique is useful 
for monitoring multiple neurotransmitters within each sample. 
12, 40, 96, 112, 114-117
 Online CE 







coupled to laser-induced fluorescence (CE-LIF) is the most popular CE method with 
microdialysis. ECD is limited to electroactive compounds, and coupling CE separation buffers 
with ESI can be difficult. The temporal resolutions obtained with microdialysis coupled to CE-
LIF can reach temporal resolutions on the s timescale. Using OPA as a fluorescent tag, Glu, Gln, 
and DA along with 5 other neurotransmitters have been separated within 20 s.
112
 With 
overlapped injection on this system, the separation time can be reduced to 14 s.
40, 121
 Although 
DA was separated and detected, the limit of detection for DA was higher than the DA 
concentration found in the dialysate. Other CE-LIF systems have been developed that are 
sensitive enough to measure DA in dialysis samples. Using NDA as the fluorescent tag, DA in 
dialysate was able to be detected in a 90 s separation using micellar electrokinetic 
chromatography (MEKC)-LIF system.
122
 MEKC is CE with micelles in the separation buffer to 
act as a pseudo-stationary phase. In this system, Glu and 10 other amino acids could be 
measured. With MEKC-LIF, amphetamine induced increases in DA were greater in the NAc of 
rats treated with leptin vs. rats treated with a vehicle injection.
123
 The increased DA stimulated 
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release was caused by an increase in DAT activity and an increase in DA release. This work with 
leptin is expanded upon in chapter 3. 
Microdialysis has a large advantage in being a robust technique. The broad range of 
analytical methods available to measure neurotransmitters in dialysis samples allows the analysis 
to be tailored to the requirements of an experiment. Like all techniques for measuring 
neurotrasnmitters, microdialysis does have several limitations. 
Limitations of microdialysis 
 One limitation of microdialysis is the temporal resolution. Most microdialysis 
experiments have temporal resolution on the min timescale. By using a segmented flow, the 
highest temporal resolution that has been achieved with microdialysis is 2 s.
109
 These values are 
high compared to electrodes which can reach 100 ms temporal resolution. 
  One large disadvantage for microdialysis measurements is the difficulty in measuring 
neuronally derived Glu. Basal Glu levels are insensitive to TTX when measured by 
microdialysis.
124
 The insensitivity of Glu is likely due to the multiple sources of Glu as well as 
the rapid uptake and regulation of Glu. Astrocytic Glu release has been shown to be a large 
contributor of basal Glu levels measured by microdialysis. Blocking the cystine-Glu antiporter, 
found on astrocytes, decreased basal extracellular concentrations of Glu in the striatum.
42
 
Although not TTX sensitive under basal conditions, microdialysis has been able to measure TTX 
sensitivity of electrically stimulated Glu
12
 and 4-aminopyridine (prolongs opening of K+ 
channels) stimulated Glu.
125
 These studies give evidence that viable Glu neurons exist within the 
vicinity of the sampling area of the probe; however, microdialysis studies of Glu are largely 
hampered by these problems.  
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Lastly, making quantitative measurements with microdialysis can be difficult. Active 
tissue processes, such as uptake, metabolism, synthesis, and release, can alter the recovery of 
probes in vivo.
126
 If the recovery is unknown, an accurate measurement of extracellular 
neurotransmitter concentrations cannot be obtained. Instead, most microdialysis experiments rely 
on approximations. Some quantitative microdialysis experiments have been developed to 
account for active tissue processes. 
Quantitative microdialysis techniques  
Neurotransmitter concentrations can be approximated by measuring the recovery of the 
probe in-vitro in a well-stirred vial and then applying that recovery to the probe in vivo; however, 
the recovery of the probe in vitro may not always match the recovery in vivo.
127, 128
 Techniques 
have been developed to measure neurotransmitters quantitatively. These include no-net-flux 
(NNF), low-flow perfusion, extrapolation to zero flow, and SIL microdialysis. Chapter 2 covers 
quantitative microdialysis techniques in more detail. Briefly, low-flow perfusion involves 
decreasing the flow rate of a dialysis probe to the point that recovery approaches 100%.
129
 The 
main disadvantage is the collection times required for slow flow rates. Additionally, the 
measurements are usually done in steady-state conditions before or after an experiment. This can 
be problematic if the recovery changes during the experiment. These limitations have hampered 
the application of low-flow perfusion. 
 Rather than directly measuring the concentration when recovery approaches 100%, the 
concentration in the brain (apparent concentration, Capp) can be quantified by varying the flow 
rate and extrapolating to a no-flow condition.
129




Figure 1.7: Procedure for quantitative microdialysis with stable-isotope labeled 
dopamine. Ed can be measured by calculating the loss of the SIL neurotransmitter 
(13C6-DA in this example) infused in the probe. With Ed calculated, Capp can be 
calculated by dividing the concentration of endogenous neurotransmitter by Ed 










concentrations of the analyte of interest are perfused through the probe (Cin).
130
 The 
concentration that is measured (Cout) is subtracted from Cin to measure the flux of the analyte. 
When Cin-Cout is plotted vs. Cin, the x-intercept is the point of NNF, where the fraction of analyte 
recovered matches the fraction of analyte that diffused out of the probe. This point is the Capp of 
the analyte in the brain. The slope of the line is the extraction fraction (Ed), the fraction of 
analyte that has diffused in and out of the probe. Ed can be calculated with the following 





 Inhibiting synthesis, release, and metabolism of DA had no effect on Ed.
126
 
NNF is a slow method that requires steady-state conditions for the entirety of the calibration. 
Thus, changes in Ed over a short amount of time cannot be accounted for. A second type of NNF, 
called dynamic NNF (dNNF) has been used to measure Capp and Ed on a faster timescale. In 
dNNF, 1 concentration of an analyte is infused through the probe during an entire experiment. 
24 
 
Multiple concentrations are infused through the probes of multiple animals and the results are 
then pooled. This technique gives higher temporal resolution but requires more animals.
132, 133
 
Additionally, variations between probes cannot be accounted for. 
133
The use of quantitative 
microdialysis has been hampered by the long time per calibration or the large amount of animals 
required for faster temporal resolution. These limitations have caused quantitative microdialysis 
techniques to be used for a small portion of experiments compared to uncalibrated microdialysis. 
A faster, more efficient quantitative method is reverse microdialysis with a calibrator 
With this method, a calibrant is perfused through the probe (Fig. 1.7). The calibrant can either be 
a homologous, biologically inactive species
134
 or a stable-isotope labeled (SIL) standard.
135, 136
 
SIL analytes are ideal because they will undergo the same processes as the endogenous species. 
Capp of the SIL analyte in the brain is known to be 0. Ed can then be measured as the loss of the 
SIL analyte ( =1- / ). With Ed measured, Capp for the endogenous species can be 
calculated with (Capp= / ). This technique has historically been used for measuring 
pharmacological drugs.
134-137
 The application of SIL microdialysis will be discussed in chapter 2.  
Evidence for Glu compartmentalization in vivo 
 In addition to making quantitative measurements, SIL microdialysis can be used to 
measure neuronal Glu. As stated above, measuring neuronal Glu release with microdialysis is 
difficult. In this thesis, we have developed an assay that can be used to measure neuronal Glu 
release (Fig. 1.8). Neuronal Glu is almost entirely derived from Gln with an enzyme called 
glutaminase, which is preferentially located within the neuron.
138, 139
 By perfusing 
13
C5-Gln 




C5-Glu can be monitored with the BzCl 





C5-Glu synthesis in neurons and astrocytes. 
13
C5-Gln that is perfused through the probe 
diffuses into the extracellular space (1) where it is taken up by neurons (2). In the neuron, 




C5-Glu (3). The 
13
C5-Glu is released from the neuron (4) where 
it can diffuse back into the probe (5) or get taken up by the astrocyte (6) where it could be converted 
to 
13
C5-Gln with glutamine synthetase (7). Based on TTX sensitivity of 
13
C5-Glu, the majority of the 
13
C5-Glu that diffuses into the membrane is neuronally derived. 
appears to be TTX sensitive, respond to mGluR agonists, and increases with a stressor. These 
responses indicate that the 
13
C5-Glu measured is neuronally derived. 
The ability to measure neurochemicals accurately in the central nervous system can be a 
valuable tool for understanding how the brain works. This thesis focuses on developing 
microdialysis to become more efficient and accurate. Using SIL neurotransmitters, microdialysis 
was used quantitatively in studying drugs of abuse and the role of leptin and DA on feeding 




In vivo calibration of microdialysis using infusion of 
stable-isotope labeled neurotransmitters 
 
Introduction 
Neurotransmitter concentrations in the extracellular space represent the balance between 
release (e.g., by exocytosis and reverse transport) and removal (e.g., by reuptake and enzymatic 
degradation). Measurement of concentration dynamics in this space is valuable for understanding 
neuronal communication. Microdialysis is a popular approach for such measurements, but its use 
is hampered by the difficulty of quantifying neurotransmitter concentrations in vivo. In this study 
we report a novel approach to measuring in vivo recovery and quantification. 
 The recovered concentration of an analyte from a microdialysis probe (Cout) is a complex 
function of concentration external to the probe (Cext) and transport into the probe. Relative 
recovery (RR), defined as Cout/Cext, can be directly measured in vitro by fixing Cext and 
measuring Cout. However, it has long been recognized that in vitro recovery, which is determined 
primarily by the probe, dialysis flow rate, analyte, and temperature, is not necessarily accurate in 
vivo.
128, 133, 140
 In particular, factors such as tissue permeability, reuptake, and metabolism will 
affect recovery in vivo. For many experiments, only the relative change of neurotransmitter is of 
interest, and impact of probe recovery is not considered; however, measurement of in vivo 
recovery and quantification, defined as determining the apparent extracellular concentration 
(Capp),
141, 142
 can be crucial to obtaining meaningful results.
126, 132, 133, 143-145
 Several methods for 
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in vivo calibration have been developed including low flow,
146, 147
 no-net-flux (NNF or Lönnroth 
method)
126, 130
 and reverse microdialysis methods.
135-137
  
In the low flow method, the dialysis flow rate is reduced so that recovery is ~100%, 
making it, in principle, independent of external processes. A related alternative is to measure 
recovery at different flow rates and extrapolate to zero flow.
129
 These methods are rarely used 
because they require long times (to either collect enough sample or to measure at different flow 
rates), but a recent innovation of using low flow to recover, then higher flow to pass sample to 
the analytical system overcomes this obstacle.
148
  
The most common in vivo calibration method is NNF. In this method, several 
concentrations of analyte are infused into the dialysis probe (Cin) while recording Cout.
126, 130
 The 
difference (Cin-Cout), which corresponds to flux across the probe membrane, is plotted against 
Cin, so that the x-intercept is the point where flux is zero. The point of NNF corresponds to Capp. 
The slope of the NNF line, (Cin-Cout)/(Cin-Capp), is extraction fraction (Ed), a measure of in vivo 
probe recovery. Providing a value for Ed is a strong advantage of the NNF method. For example, 
it has been shown that the Ed of  DA ( ) is relatively insensitive to inhibition of release, 
synthesis, and metabolism but strongly affected by uptake inhibition.
126
 This insight allows  
to be an indirect measure of DA uptake in vivo. Knowledge of Ed can also be helpful in 
interpreting changes in Capp. If a drug or genetic manipulation evokes a change in Capp, it is not 
clear if the difference is related to altered release or reuptake; however, knowledge of Ed can aid 
interpretation. For example, acute ethanol was shown to increase DA concentration recovered in 
the nucleus accumbens. After showing no change in , the increase in  could be attributed 





Despite the appeal of NNF, it suffers from several disadvantages. By requiring infusion 
of several concentrations it is time consuming. Further, it assumes that recovery is constant over 
the course of the experiment; however, the recovery of the probe can change under different 
conditions. For example if uptake is inhibited by a systemic drug injection then uptake and 
recovery will change as the drug concentration changes.
132
 This effect can be accounted for by 
using dynamic NNF (dNNF) in which one concentration of a neurotransmitter is perfused 
through the probe for one animal.
132, 133
 By infusing different animals with different 
concentrations and then pooling animals at different concentrations, a NNF trace can be 
calculated for each time point. dNNF allows for the measurement of Ed and Capp under transient 
conditions; however, a large number of animals are required. Further, it assumes minimal probe 
variability and precludes observation of individual differences. 
In vivo calibration can also be achieved by using reverse microdialysis. In this case, 
calibration is achieved before (or after) an experiment by infusing the target compound through 
the probe in vivo while Capp is known to be zero. Measuring Cout, allows a direct measurement of 
the loss or extraction of analyte by the sample (e.g., brain) and calculation of Ed. This value can 
be used to quantify results in that subject during an experiment. The method is readily used for 
exogenous chemicals, such as drugs; however, it cannot be used for neurotransmitters which 
cannot be removed from the brain to give a Capp = 0. This method also assumes that recovery is 
constant over the course of the experiment.  
 A variation of this method is to continuously infuse a similar but distinguishable form of 
the compound through the probe. Every fraction collected then allows determination of Ed of the 
infused compound (which has Capp = 0) which can then be used to quantify the Capp for the target 
analyte. For example, ropivacaine was infused to measure Ed and then quantify bupivacaine, 
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which differs by 1 methyl group from ropivacaine.
134
 This approach assumes that the modified 
form behaves identically to the actual analyte. A better standard to infuse is a stable-isotope 
labeled (SIL) form. In a SIL microdialysis experiment, the concentration of the labeled analyte in 
the brain ( ) = 0 so that Ed can be calculated directly: 
     (1) 
Because Ed of the analyte is equal to  the apparent concentration can be calculated by: 
     (2) 
where  is the concentration of endogenous analyte. This approach has been previously 
used with drugs. For example, d3-morphine and 
13
C4-cortisone have been infused to monitor Ed 
of these drugs and quantify them in vivo.
135, 136
  
Microdialysis with SIL neurotransmitters has not been reported but it would be expected 
to be especially useful because neurotransmitters are the most frequent target of microdialysis 
measurements. Reverse microdialysis of SIL neurotransmitters would also allow dynamic 
changes in Ed to be recorded. Here we describe the use of this method for DA and glutamate 
(GLU). 
13
C forms of these compounds were infused constantly during experiments allowing 
calculation of Ed at every time point. At the same time, the endogenous 
12
C form of each 
neurotransmitter was collected. The different forms of each compound were measured and 
distinguished using liquid chromatography-mass spectrometry. Comparison to NNF revealed that 
the SIL microdialysis method yields equivalent results. An important advantage of the SIL 
method is that it allows in vivo correction for in vivo extraction of every dialysate sample with no 




Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise noted. Artificial cerebral spinal fluid (aCSF) comprised of 145 mM NaCl, 2.68 mM 
KCl, 1.01 mM MgSO4, 1.22 mM CaCl2, 1.55 mM Na2HPO4, 0.45 mM NaH2PO4 (Fisher 
Scientific, Pittsburgh, PA). 
13
C6-DA was purchased from CDN isotopes (Quebec, Canada) and 
13
C5-GLU was purchased from Cambridge Isotopes (Andover, MA). Mobile phase of the LC 
column included 10 mM ammonium formate and 0.15% formic acid. Cocaine hydrochloride was 
purchased from the University of Michigan Hospital (Ann Arbor, MI). 
Microdialysis probes 
Probes were constructed as previously described.
149
 In summary, 40/100 µm (i.d./o.d.) 
fused silica capillaries (Polymicro Technologies, Phoenix, AZ) were glued side-by-side with a 2 
mm offset. The capillaries were ensheathed in a regenerated cellulose membrane with both ends 
sealed by polyimide sealing resin (Grace, Deerfield, IL). Flow rate of perfusion fluid through the 
probe was 1 µL/min unless stated otherwise. 
Sample derivatization and analysis 
Each sample was derivatized with benzoyl chloride and analyzed as described 
previously.
68
 Briefly, 5 µL samples were sequentially mixed with 2.5 µL of 100 mM sodium 
tetraborate, 2.5 µL of benzoyl chloride (2% in acetonitrile, v/v), and 2.5 µL of internal standard. 
Internal standard comprised of 10 µM GLU and DA reacted with 
13
C6-benzoyl chloride (CDN 
Isotopes) in 100 mM sodium tetraborate. The internal standard was the diluted 1:100 in DMSO 
and 1% formic acid (v/v). Between each reagent addition, the samples were vortexed. The 
samples were analyzed on a Waters UPLC system with a Waters HSS T3 column (1 mm x 100 
mm, 1.8 µm). A Waters/Micromass Quattro Ultimatriple quadrupole or an Agilent 6410 triple 
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quadrupole mass spectrometer was used for detection. Mobile phase A was 10 mM ammonium 
formate and 0.15% (v/v) formic acid in water. Mobile phase B was acetonitrile. The peak areas 
of each analyte were divided by the area of the internal standard. The limits of detection for DA 
and GLU were 0.03 nM and 5 nM, respectively.
68
 These limits of detection for this method are 




Measuring in vitro loss and recovery 
For in vitro studies, 200 nM 
13
C6-DA was perfused through probes at flow rates of 0.2, 
0.5, 1.0, and 1.5 µL/min. The probe sampled from a well-stirred vial of 200 nM 
12
C-DA. The 
recovery of the 
12
C-DA was compared to the loss of the 
13
C6-DA at each flow rate. Samples were 
collected every 5 min with 3 replicates of each flow rate and 3 probes were tested. 
Surgery 
Male Sprague-Dawley rats were anesthetized with ketamine (65 mg/kg, Fort Dodge 
Animal Health, Fort Dodge, IA) and dexdomitor (0.25 mg/kg, Pfizer Animal Health, New York, 
NY) and placed in a stereotaxic frame. A burr hole was drilled where the cannula (Plastics One, 
Inc., Roanoke, VA) was being implanted (+1.6 A/P, ±1.1 L, cannula aimed to nucleus 
accumbens).
150
 The rats were uni-laterally cannulated. Cannulae were implanted alternately 
between the left and right side of the brain. Additional burr holes were drilled for skull screws to 
hold the cap in place. The cannula was lowered 4 mm from the top of the skull and dental cement 
(A-M Systems, Inc., Sequim, WA) was used to hold the cannula in place. A stylet (Plastics One, 
Inc.) was inserted into the cannula and the rat was allowed to recover for 5 to 10 days prior to the 
experiment. All animal procedures were approved by the University Committee for the Use and 
Care of Animals at the University of Michigan. 
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The day before the experiment, a microdialysis probe was perfused with aCSF at a flow 
rate of 1 µL/min. The rat was lightly anesthetized in an isofluorane drop box. The probe was 
inserted into the cannula with the active area extending 2 to 4 mm past the cannula to sample 
from the nucleus accumbens. Probe placements were checked with histology (data not shown). 
The rat was tethered to a Raturn (Bioanalytical Systems, Inc., West Lafayette, IN). Overnight, 
the flow rate was lowered to 0.2 µL/min. 
Measuring extraction fraction of DA and GLU 
On the day of the experiment, the flow rate of the probe was increased to 1 µL/min. 
Varying concentrations of 
13
C6-DA (0, 5, 20, 200, 500 nM) were perfused through the probe with 
and without 5 µM nomifensine. Solutions were switched by hand by disconnecting the fluid line 
and reattaching another syringe. The time required for the liquid to travel from the syringe to the 
probe was approximately 10 min. Each concentration of DA was allowed to equilibrate for 10 
min prior to sampling, as was performed in previous NNF calibrations.
126
 Each fraction was 5 µL 
and at each concentration 3 samples were collected. The same procedure for DA was performed 
with GLU. 
13
C5-GLU at varying concentrations (0, 0.2, 2, 5, and 10 µM) was perfused through 
the probe. Although a Raturn was used for all experiments, liquid swivels could be used as well. 
The internal volume of liquid swivels may be a concern for fast temporal resolution of SIL 
microdialysis, but no more than that of conventional microdialysis. 
An injection of cocaine (20 mg/kg, i.p.) was administered to the rat to show the effect of 
a DA uptake inhibitor under transient conditions. The probe was perfused with 200 nM 
13
C6-DA 
for the duration of the experiment. 200 nM 
13
C6-DA was chosen because it produced a large 
signal so that smaller changes in  could be measured.  and  were measured on every 
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sample, which were collected every 5 min. As a control, saline (i.p.) was administered to the rat 
rather than cocaine. 
To show the effect of an uptake inhibitor on  under transient conditions, 750 µM 
PDC (Tocris, Bristol, UK) was perfused through the probe along with 2 µM 
13
C5-GLU.  and 
 were measured during the PDC infusion. The doses and modes of delivery for cocaine and 
PDC were chosen to replicate doses and modes of delivery of previous studies to show how SIL 




For comparison of NNF to SIL microdialysis, t-tests were performed. Paired t-tests were 
used for the DA measurements because rats were used as their own control between vehicle and 
uptake inhibitor perfusion. For GLU studies, unpaired t-tests were used because not all rats were 
matched with the PDC perfusion. When comparing the non-calibrated vs. calibrated GLU/DA 
concentrations, a linear mixed model regression was used to test significance. Analysis of 
variance (ANOVA) could not be used because for most of the experiments described in this 
study, the same rat was used in multiple groups (e.g. calibrated and not calibrated). The multiple 
measurements on a single rat violate the assumption of independence between groups; however, 
a repeated measures ANOVA may have sufficed. The mixed model regression was used because 
it has less strict assumptions than a repeated measures ANOVA, but provides similar results.
151
 
SPSS (IBM, Armonk, NY) was used for the mixed model regression. The rat ID was used as the 
subject, calibration was used as a factor, time was used as a covariate, and the measurement (e.g. 
Ed, % basal, concentration) was tested as the dependent variable. 
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Figure 2.1: In vitro recovery of stable-isotope labeled 
dopamine. 200 nM 
13
C6-DA was perfused through the probe 
sitting in a well stirred vial of 200 nM 
12
C-DA. The loss of the 
13
C6-DA was compared to the recovery of the 
12
C-DA across 4 
flow rates (0.2, 0.5, 1.0, and 1.5 µL/min). The recovery 
matched the loss at each flow rate, showing diffusion rates in 
vitro are equal. 
Results 
In vitro SIL microdialysis 
In principle, relative loss of 
13
C6-DA should be the same as relative recovery of 
12
C-DA 
that is being sampled. To test this idea, 200 nM 
13
C6-DA was perfused through a probe sampling 
from a well-stirred solution of 200 nM 
12
C-DA. The relative loss of 
13
C6-DA was within 10% of 
the recovery of 
12
C-DA across a range of flow rates showing that transport to and from the probe 
in vitro was equivalent (Fig. 2.1).  
Effect of infused transmitter on endogenous neurotransmitter 
Both NNF and SIL microdialysis rely on infusing a neurotransmitter through the dialysis 
probe. Such compounds may affect the process being measured by activating receptors (e.g., 
autoreceptors) or by affecting uptake (e.g. saturating uptake). To determine if infusion of 
neurotransmitter affected endogenous levels, we infused SIL neurotransmitter while monitoring 
the endogenous form being collected from the nucleus accumbens. For concentrations typically 
used for NNF, the infused SIL 
form had no effect on the 
concentration of the 
12
C form 
(e.g., endogenous form) 
collected for both GLU and DA 
(see Fig 2.2). This result 
confirms the conclusion 
previously reached for lack of an 
effect by infused DA on DA 
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Figure 2.2: Effects of stable-isotope labeled 
neurotransmitters on endogenous concentrations. 
(A) When varying concentrations of 
13
C6-DA 
perfused through the probe, 
12
C-DA measured 
remained constant. The dotted line indicates the 
 when =0 and the grey bars represent 
the SEM with no 
13
C6-DA perfused (N=5, error 
bars are SEM). (B) Perfusing up to 10 µM 
13
C5-
GLU had no effect on the endogenous 
concentration of GLU. The dotted line and grey 
bar indicate  when =0. N=5, error 
bars show SEM. 
during NNF and extends it to GLU.
126
  
In vivo SIL microdialysis 
We next sought to determine if Ed and 
Capp measured by SIL microdialysis of 
13
C 
labeled neurotransmitters would be equivalent 
to that measured by NNF. For these 
experiments, the 
13
C labeled neurotransmitter 
was infused at different concentrations and Ed 
was calculated using equation 1 for each 
concentration infused. For NNF, Cin was the 
concentration of 
13
C labeled neurotransmitter 
perfused through the probe and Cout was 





DA]. The same method was used for GLU. 
By NNF  = 0.24 ± 0.02 (Fig 2.3A) and 
 = 0.26 ± 0.02 (Fig 2.4A). The average 
 measured by SIL microdialysis was 0.26 
± 0.03, 0.25 ± 0.02, 0.24 ± 0.02, and 0.25 ± 
0.02 with 5, 20, 200, and 500 nM 
13
C6-DA 
infused, respectively (Fig 2.3B). In principle 
the highest possible Ed value is that for a well-stirred solution in vitro.
141
 It has previously been 
found that in the nucleus accumbens  approaches the maximal values, likely because of the 
effects of high uptake rates.
143
 In agreement with these previous observations, our in vivo values 
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were not statistically different from the in vitro value of 0.22 ± 0.003 at the same flow rate 
shown in Fig. 2.1. The slight differences are most likely due to the variability inherent in probes. 
The average  measured by SIL microdialysis was 0.28 ± 0.04, 0.29 ± 0.01, 0.27 ± 0.03, and 
0.25 ± 0.02 with 0.2, 2, 5, and 10 µM 
13
C5-GLU infused, respectively (Fig 2.4B). The Ed 
measured by NNF and SIL microdialysis (at all concentrations) were not statistically different 
and were on average within 5% of each other. These results show that Ed was not affected by the 
concentration infused and SIL microdialysis was equivalent to NNF under these conditions. 
With Ed calculated and the dialysate concentration of neurotransmitter measured, Capp 
could be calculated. By NNF,  in the nucleus accumbens was calculated to be 13 ± 2 nM. 
Using SIL microdialysis (equation 2),  was measured to be 11 ± 2, 12 ± 3, 13 ± 3, and 12 ± 3 
nM for 5, 20, 200, and 500 nM 
13
C6-DA infused, respectively (Fig 2.3C). These concentrations 
match well with previously reported results for NNF measurements of DA in the nucleus 






 and 5.2 nM.
152
 The values also 
match well the concentration determined by signal averaging DA transients over several min in 
the nucleus accumbens with fast-scan cyclic voltammetry. By averaging the transients, the 
extracellular DA concentration was estimated to be ~20 nM.
72
  
 was calculated to be 1.0 ± 0.4 µM using NNF. Using SIL microdialysis,  was 
calculated to be 1.1 ± 0.5, 1.0 ± 0.3, 1.0 ± 0.3, and 1.2 ± 0.4 µM with 0.2, 2, 5, and 10 µM  
perfused through the probe, respectively (Fig 2.4C).  and  measured with NNF were 
within 8% that measured by SIL microdialysis and were not statistically different showing that 
these methods give equivalent results for both neurotransmitters. Our values fell within 





Figure 2.3: Quantitative microdialysis with stable-isotope labeled dopamine 
compared to no-net-flux. (A) A representative NNF curve from one rat 
shows how perfusing nomifensine through the probe (black open circles), 
(the slope) reduces  and increases  (x-intercept). (B)  was 
compared between SIL microdialysis calibration and NNF calibration. 
Nomifensine reduced  as measured by both calibration techniques. (C) 
 was calculated using equation 2. At all concentrations of 
13
C6-DA 
perfused,  matched the NNF values. Error bars show SEM (n=5 for each 
group). Paired t-tests were used for comparison. ** indicates p-value < 0.01 
and * indicates p-value < 0.05. 




GLU in the nucleus 




reported that  is 
largely governed by 
reuptake so that 
uptake inhibition 
causes  to 
decrease.
126
 As a 
result, if  is 





either in absolute 
concentration or by 
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percent of baseline during uptake inhibition. The effect of uptake inhibition is rationalized by 
considering that DA is primarily removed from the extracellular space via uptake so that 
decreasing the uptake will lower the concentration gradient between the extracellular space and 
the probe. To determine if SIL microdialysis and NNF offered equivalent responses to this 
perturbation, we blocked uptake by perfusing 5 µM nomifensine through the probe at all 
13
C6-
DA concentrations infused. As shown in Fig 2.3, nomifensine decreased  by 30% as 
measured by both NNF and SIL microdialysis. With nomifensine in the probe,  was 
calculated to be 0.17 ± 0.2 using NNF. With SIL microdialysis,  was calculated to be 0.18 ± 
0.03, 0.16 ± 0.02, 0.18 ± 0.02, and 0.18 ± 0.01 with 5, 20, 200, and 500 nM 
13
C6-DA perfused 
through the probe. As expected,  increased with nomifensine. Using NNF,  was 
calculated to be 80 ± 20 nM. Using SIL microdialysis,  was calculated to be 86 ± 16, 87 ± 
14, 83 ± 15, 91 ± 18 nM for 5, 20, 200, and 500 nM 
13
C6-DA perfused through the probe, 
respectively. 
 Similar to ,  has also been shown to be controlled by reuptake.
131
 To determine 
if a change in  could be measured by SIL microdialysis during uptake inhibition, we 
perfused 750 µM of the GLU uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC) 
through the probe and performed SIL microdialysis using 2 µM 13C5-GLU. As shown in Figure 
2.4B and 2.4C,  was decreased by 40% as measured by SIL microdialysis (p < 0.001) while 
 increased 550% (p < 0.005). These results show that: 1) SIL microdialysis and NNF 
provide equivalent results during uptake inhibition; and 2) uptake inhibition decreases  
similar to .  
Ed changes under transient conditions 
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Figure 2.4: Quantitative microdialysis with stable-isotope 
labeled glutamate compared to no-net-flux. (A) Sample NNF 
curve is shown when perfusing varying concentrations of 
13
C5-
GLU through the probe. (B) SIL microdialysis was compared 
to NNF to measure .  SIL microdialysis values 
matched that of the NNF values. 750 µM PDC was perfused 
with 2 µM 
13
C6-DA, which decreased  (p<0.001, 
unpaired t-test). (C)  and [
12
C-GLU measured] were used 
to calculate .  for SIL microdialysis matched  
measured by NNF. After perfusion of 750 µM PDC,  
increased 550% (p-value < 0.001). Error bars show SEM (n=5 
except for PDC infusion, n=4). 
The above results show 
that uptake inhibition affects Ed 
and therefore interpretation of 
the magnitude of dialysate 
concentrations that are detected. 
It is reasonable to expect that 
uptake inhibition is steady during 
drug infusion through a probe; 
however, it will change during a 
systemic injection due to 
pharmacokinetics. To 
demonstrate that SIL 
microdialysis could monitor 
dynamic changes in Ed, we used 
the method to follow  and 
 during systemic cocaine 
injection (20 mg/kg, i.p.) while 
infusing 200 nM 
13
C6-DA 
through the probe for the 
duration of the experiment. As 
shown in Fig 2.5,  decreased 
by an average of 35% within 20 
min of cocaine injection (p-
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Figure 2.5: Quantitative microdialysis of dopamine under 
transient conditions. (A)  was measured during a cocaine 
challenge. At t=0, cocaine (20 mg/kg i.p., black solid circles) or 
saline (grey solid circles) was administered.  was reduced 
by 35% (p-value < 0.005) in the presence of cocaine compared 
to saline. (B) [
12
C-DA measured] (right axis, black open 
circles),  with a constant  assumed (  measured 
prior to cocaine injection, grey solid circles), and  
measured with SIL microdialysis calibration (black solid 
circles) are shown when cocaine was administered. [
12
C-DA 
measured] was also measured after saline injection (right axis, 
black solid squares). (C) Calibrated (black solid circles) and 
conventional (black open circles) microdialysis was measured 
in % basal of 
12
C-DA after cocaine injection. N=7 and error 
bars show SEM. ** indicates p- value < 0.01 and * indicates p-
value < 0.05. 
value<0.005 using the mixed 
model regression) compared to 
saline injection, similar to 
previous reports using 
dNNF.
132
 For the first 20 min 
after cocaine injection  was 
lower than after saline injection 
(p-values<0.05, 0.005, 0.05, 
and 0.005 for the fractions 
collected at 5, 10, 15, and 20 
min after injection using 
unpaired t-test). 
Because  was 
changing following cocaine 
injection, the SIL microdialysis 
method reported a higher  
than if it were measured 
assuming a constant  
(where  was measured prior 
to cocaine injection) as shown 
in Figure 5. Using mixed model 
regression, the SIL 
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microdialysis  was measured to be 160% greater on average compared to a constant  
over the first 20 min of sampling following cocaine injection (p < 0.001). In addition, the relative 
increase in  was 160% higher when calibrated by SIL microdialysis compared to a constant 
 over the first 20 min of drug (p < 0.001). The peak increase as a percent of basal with 
calibrated DA was measured to be 190% higher than the non-calibrated measurement (p-value < 
0.05).  
While quantitative microdialysis has been used previously to measure  under 
transient conditions, no previous reports have demonstrated such measurements for  or 
. To show how SIL microdialysis can measure  and  under transient conditions, 
we monitored both as PDC was perfused through the probe. Mixed model regression showed a 
45% decrease of (p-value < 0.001) after PDC was perfused through the probe (Fig 2.6). 
With calibration at each point by SIL microdialysis,  was measured to be 190% higher than 
if assuming a constant  (  measured with SIL microdialysis prior to PDC perfusion, p-
value < 0.001 using the mixed model regression). Using a paired t-test, 3 of the 4 calibrated 
microdialysis fractions had statistically higher  (p-value < 0.05, 0.05, and 0.005 for 10, 15, 
and 20 min after PDC infusion, respectively). This effect was extended to relative changes as 
well. Calibrated by SIL microdialysis, the percent basal change was 2-fold larger compared to 
non-calibrated measurements (p-value < 0.001 using mixed model regression model, refer to Fig 
2.6C). Thus, even relative changes are in error when not using calibration. 
The experiments show that SIL microdialysis and NNF provide equivalent Capp and Ed 
for two different neurotransmitters across a wide range of conditions. This result is in good 
agreement with expectation since the techniques both rely on the principle of measuring the 
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extraction or loss of a molecule of interest from the probe in the in vivo environment. Because of 
this equivalency, the methods not only provide the same information, but are subject to the same 





SIL microdialysis is an efficient method 
 The largest disadvantage to performing NNF is the added time and expense needed to 
complete a study. For example, a previous report showing that PDC lowers  required 7 h of 
fraction collection time when using NNF.
131
 With SIL microdialysis of 
13
C5-GLU, the same 
measurement with the same number of replicates required 30 min. If dNNF were to be used to 
capture the dynamics of , a minimum of 3 concentrations of perfused GLU would be 
needed requiring 12 animals assuming 4 replicates for each [GLU]in. In contrast, the SIL 
microdialysis method required 4 animals for an equal number of replicates. Using SIL 
microdialysis is more efficient in terms of time and animal usage than NNF. In addition to time 
saved for a single analyte, multiple analytes could be used for SIL microdialysis simultaneously 
saving further time. The benzoyl chloride derivatization and HPLC-MS method described herein 
allows for quantifying multiple SIL neurotransmitters in a single sample.
68
 The ease of use with 
SIL microdialysis is compromised by the need for a mass spectrometer to perform these 
measurements; however, as mass spectrometers become more available, this disadvantage will 
wane.  
Apart from the time and work saved, SIL microdialysis with 
13
C labeled 
neurotransmitters also allows monitoring for artifacts that may be caused by perfusing 







Figure 2.6: Quantitative microdialysis of glutamate under 
transient conditions. (A)  was measured as 750 µM PDC 
was perfused (grey line) through the probe.  (black solid 
circles) values reached the minimum value within 5 min (p-
value < 0.001 compared to aCSF). With 2 µM 
13
C5-GLU 
perfused through the probe, the addition of PDC to the 
perfusate increased [
13
C5-GLU measured] (right axis, black 
open circles). (B) [
12
C-GLU measured] (right axis, black open 
circles),  with constant  assumed (  measured 
prior to PDC, grey solid circles), and  (black solid circles) 
were measured as PDC was perfused. (C) % baseline of GLU 
for calibrated (black solid circles) vs. conventional (black open 
circles) microdialysis is shown. Error bars show SEM (n=4). 






C5-GLU, we determined that 
the concentrations perfused had 
no measureable effects on 
endogenous DA and GLU. Thus 
it is possible to directly show 
that the calibration method does 
not perturb the system being 
sampled. 
Use of Ed to aid in data 
interpretation 
The availability of a 
more efficient method for 
measuring Ed in vivo may 
enable quantitative 
microdialysis studies to be more 
routinely performed. Such 
quantification may be 
significant for many studies. 
The use of Ed can help discern 
the source of a concentration 
change. For example, one study 
44 
 
showed that  was constant for two days allowing concentration changes to be related to 
endogenous changes rather than artifacts of recovery change.
143
 In another study, ethanol was 
shown to increase DA and GLU in the nucleus accumbens and the hippocampus.
131, 133
 By 
showing that Ed did not change (requiring 24 animals, 2 h for each animal for DA and 13 
animals, 7 h for each animal for GLU), it was possible to demonstrate the change in 
concentration is induced by release and not a decrease in reuptake. In principle, similar studies 
by SIL microdialysis could significantly save on animals and time required. Quantification may 
also be important for determining effects of genetic manipulation. For example, distinguishing 
the dose-dependent effects of SERT gene on extracellular serotonin concentration required 
calibrated microdialysis measurements.
145
 The heterozygous SERT knockout showed no 
difference in basal serotonin concentrations in the striatum using uncalibrated microdialysis 
compared to the wild type; however, when using NNF the heterozygous SERT knockout was 
shown to have an increased  compared to the wild type. We may expect that other 
genetic modifications may also result in more subtle changes in neurotransmitter concentration 
that are best detected by quantification. The availability of SIL microdialysis could aid in such 
studies.  
Quantification may also be important when comparing techniques. The relative DA 
increase measured in the nucleus accumbens by microdialysis following a 3 mg/kg dose of 
cocaine I.V. was an order of magnitude lower than that observed by voltammetry.
73, 156
 While 
some of the difference may be attributed to differences in temporal resolution (peak changes may 
happen quickly and be recorded by voltammetry but are averaged resulting in lower values by 
microdialysis), some difference must also be due to use of non-calibrated microdialysis probes in 
these studies. As shown here and elsewhere, lack of calibration can result in substantial 
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underestimation of extracellular concentrations and relative increases by microdialysis.
126
 It is 
clearly desirable to use in vivo calibration if comparing different methods. The use of SIL 
microdialysis in such studies will reduce the time and animal cost associated with the 
measurements and therefore enhance the feasibility of such comparisons. 
Conclusions 
Quantification by in vivo calibration is an important tool for microdialysis measurements. 
A robust and efficient new method for measuring Ed and Capp of neurotransmitters has been 
demonstrated using SIL microdialysis. Using SIL microdialysis provides a more accurate 





In vivo evidence for increases in dopamine uptake and release in the  
nucleus accumbens after an acute leptin injection 
 
Introduction 
Leptin is a hormone released by adipocytes that is involved in controlling feeding and 
energy expenditure.
27, 157, 158
 Mice lacking the leptin gene (ob/ob) eat excessively and become 
obese.
27
 Leptin treatments have been shown to reverse hyperphagia in multiple species. Chronic 
injections of leptin caused a 30% reduction in body weight in ob/ob mice after 2 weeks and a 
12% weight loss in wild-type mice.
30
 An injection of leptin over 24 h into the ventral tegmental 
area (VTA) decreased food intake of rats.
157
 Similarly, rats that received chronic 
intracerebroventricular (i.c.v.) infusions also decreased food intake.
159
 In humans, treating a male 
adolescent that had congenital leptin deficiency with recombinant leptin increased energy 
expenditure and reduced body fat.
32
  
An important question is if leptin modulates feeding behavior through effects on the 
rewarding or motivating effects of food. Because mesolimbic dopamine (DA) is a critical 
component of reward pathways,
160-162
 considerable attention has focused on the possible 
modulation of DA in this pathway by leptin.
123, 163, 164
 A reasonable hypothesis is that one of 
leptin’s actions is to decrease the rewarding aspects of food by suppressing DA signaling. 
Several lines of evidence suggest that leptin affects reward pathways. When food deprived rats 
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underwent sucrose-conditioned place preference training, they showed preference for the 
compartment where low calorie sucrose pellets were dispensed. With a chronic treatment (7 
days, 125 µg/kg/day) of leptin, the food deprived rats no longer displayed a place preference.
165
 
The authors concluded that leptin decreased the reward value of food. The effect of leptin on 
reward seeking behavior was also established with a brain stimulation reward (BSR). Food 
deprived rats with access to a lever that delivered a BSR required a lower frequency BSR to 
achieve the same number of lever presses as rats fed ad-libitum.
164, 166
 The lower the body 
weight, the lower the stimulation frequency required. Leptin injected into the right lateral 
cerebral ventricle increased the frequency of BSR required for lever presses in food deprived 
rats,
164
 demonstrating that leptin affected the reward circuitry of the brain. 
Direct links of leptin to DA signaling have been found as well. Leptin receptors have 
been found on dopaminergic neurons in the VTA and the lateral hypothalamus, which innervates 
the midbrain.
35
 The presence of these leptin receptors causes the effects of drugs of abuse to be 
modulated by leptin. Rats given chronic infusions of leptin (12 µg/day, ICV) had greater 
amphetamine-induced locomotor activity than rats given vehicle.
159
 In ob/ob mice, amphetamine 




Exactly how leptin affects DA in the brain remains unresolved. Brain slices from ob/ob 
mice released less DA during electrical stimulation in the nucleus accumbens (NAc) than wild-
type mice.
163
 Differences in tyrosine hydroxylase (TH) levels caused by leptin have been 
observed in areas of the brain associated with reward. For example, ob/ob mice have lower TH 
levels in the NAc than wild type mice.
163
 After leptin treatments, the TH levels increased in both 
the NAc and the VTA.
34, 163
 Even with these differences observed in vitro, no differences in 
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extracellular basal DA concentrations in microdialysis samples from the NAc and cocaine 
induced elevated DA were measured between ob/ob and wild-type mice.
167
 In agreement with 
Roseberry, no differences in D2 binding in brain slices from the same brain region were detected 
between ob/ob and wild-type mice.
168
 These studies compared mice that were genetically 
different. An absence of leptin for the entire lifetime of ob/ob mice may affect neurochemical 
measurements. Additionally, many of the studies were performed in brain slices which can also 
affect neurochemical measurements. 
Performing experiments on intact animals with normal leptin regulation can provide 
further insights into how leptin affects the DA system. In rats, peripheral leptin altered DA 
activity in multiple locations of the mesolimbic system. Leptin microinjected into the VTA 
caused reduced firing of DA neurons in the VTA.
157
 Additionally, acute leptin (1 µg, ICV) 
decreased the extracellular concentration of DA by 40% in the NAc of food deprived rats as 
measured by microdialysis.
169
 This decrease was hypothesized to be due to hyperpolarization of 
lateral hypothalamic (LH) DA neurons and inhibition of DA release in rat hypothalamic neural 
endings based on in vitro studies; however, leptin has also been shown to depolarize LH 
neurons,
36
 which confounds the cause of decreased extracellular DA. When these food deprived 
rats were given food, leptin decreased the amount of DA released compared to vehicle treated 
rats. 
In a separate study measuring acute leptin effects on intact rats fed ad-libitum, an acute 
peripheral leptin injection increased amphetamine induced DA release in the NAc. In this study, 
TH and DA active transporter (DAT) activity were shown to increase in vitro after leptin 
injection. The effect of amphetamine was attributed to both an increase in DA synthesis and 
DAT activity (amphethamine reverses DAT therefore more active protein will evoke a greater 
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DA release into extracellular space).
123
 Interestingly, despite apparent increases in TH and DAT, 
no detectable effect of leptin on basal DA concentrations was measured. This result was 
surprising because DAT is believed to be a principal controller of extracellular DA 
concentration. It was concluded that increased TH activity counterbalanced the increased uptake 
and netted a result of no change in DA basal levels. 
To better understand how leptin modulates DA concentrations in vivo, we used 
microdialysis measurements of DA and its metabolites, and pharmacological experiments 
designed to distinguish effects of increased TH and DAT activitiy in the NAc of fed Sprague-
Dawley rats. In this study, changes in basal DA concentrations were measured with a 
quantitative microdialysis technique. This method reveals a net decrease in extracellular DA 
concentration following an acute leptin injection. To determine the mechanism of this decrease, 
cocaine and raclopride were infused through the probe with or without leptin. These experiments 






All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise noted. Artificial cerebral spinal fluid (aCSF) was comprised of 145 mM NaCl, 2.68 
mM KCl, 1.01 mM MgSO4, 1.22 mM CaCl2, 1.55 mM Na2HPO4, and 0.45 mM NaH2PO4 
(Fisher Scientific, Pittsburgh, PA). 
13
C6-DA was purchased from CDN isotopes (Quebec, 





Probes were constructed as previously described. 
149
 Briefly, 40/100 µm (i.d./o.d.) fused 
silica capillaries (Polymicro Technologies, Phoenix, AZ) were glued side-by-side with a 2 mm 
offset. The capillaries were ensheathed in a regenerated cellulose membrane with both ends 
sealed by polyimide sealing resin (Grace, Deerfield, IL). Flow rate of perfusion fluid through the 
probe was 1 µL/min. 
Male Sprague-Dawley rats were anesthetized with ketamine (65 mg/kg, Fort Dodge 
Animal Health, Fort Dodge, IA) and dexdomitor (0.25 mg/kg, Pfizer Animal Health, New York, 
NY) and placed in a stereotaxic frame. A burr hole was drilled where the probe was being 
implanted (+1.6 A/P, ±1.1 L, probe aimed to sample from NAc).
150
 The probes were bi-laterally 
implanted. The measurements for both probes in each animal were averaged. Additional burr 
holes were drilled for skull screws to hold the cap in place. The probe was lowered 8 mm from 
the top of the skull and dental cement (A-M Systems, Inc., Sequim, WA) was used to hold the 
probes in place. Animals were allowed to acclimate in the testing chamber for 24 h prior to 
testing. All animal procedures were approved by the University Committee for the Use and Care 
of Animals at the University of Michigan. 
The day of the experiment, rats were lightly anesthetized in an isofluorane drop box 
while the probes were attached to the fluid lines. The microdialysis probe was perfused with 
aCSF at a flow rate of 1 µL/min for at least 1 h before the experiments began. Probe placements 
were checked with histology (data not shown). Rats were tethered to a Raturn (Bioanalytical 
Systems, Inc., West Lafayette, IN) during testing. 
Sample derivatization 
Each sample was derivatized with benzoyl chloride and analyzed as described 
previously.
68
 Briefly, samples were sequentially mixed with, 100 mM sodium tetraborate, 
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benzoyl chloride (2% in acetonitrile, v/v), and internal standard in a 2:1:1:1 volume ratio. 
Internal standard comprised of 10 µM DOPAC, 3-MT, HVA, and DA reacted with 
13
C6-benzoyl 
chloride (CDN Isotopes) in 100 mM sodium tetraborate. The internal standard was diluted 1:100 
in DMSO and 1% formic acid (v/v). Between each reagent addition, the samples were vortexed. 
Samples were analyzed on a Waters UPLC system with a Waters HSS T3 column (1 mm x 100 
mm, 1.8 µm). An Agilent 6410 triple quadrupole mass spectrometer was used for detection. 
Mobile phase A was 10 mM ammonium formate and 0.15% (v/v) formic acid in water. Mobile 
phase B was acetonitrile. The peak areas of each analyte were divided by the area of the internal 
standard. 
Quantitative microdialysis 
For quantitative DA measurements, 200 nM 
13
C6-DA was perfused through probes. The 
extraction fraction ( ) was calculated with the following equation: 
 
where  is the concentration of stable-isotope labeled (SIL) DA that exits the outlet of the 
probe and  is the concentration of 
13
C6-DA that is infused into the probe.
126, 143, 170
 With  
calculated, the apparent concentration ( ) of DA could be calculated with the following 
equation: 
 
where  is the concentration of endogenous DA measured.  and  were both 
measured in an awake, conscious rat prior to a leptin or vehicle treatment. Leptin (1 mg/kg, i.p.) 
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or phosphate buffered saline (PBS, 20 mMphosphate pH 5.2, 0.13 M NaCl) vehicle injection 
(i.p.) was administered and  and  were each measured again after 4 h. 
To determine the rate of production of DA metabolites, the syringe containing aCSF was 
switched to a syringe with 200 nM 
13
C6-DA using a 4-port valve (Valco Instruments, Houston, 
TX). After 7 min of 
13
C6-DA infusion, the 4-port valve was switched back to the syringe 
containing aCSF. The 
13
C6-DA infusion was performed before and 4 h after a leptin (1 mg/kg, 






C6-HVA. Fractions were collected every min and derivatized. 
Measuring changes in uptake and release after leptin treatment 
 To measure how uptake is affected by leptin, rats were given a single injection of leptin 
(1 mg/kg, i.p.) or PBS (i.p.) 3.5 h prior to measurements. Basal levels were then collected for 30 
min. A 4-port valve was then switched to deliver 100 µM raclopride. Samples were collected for 
an additional 30 min with raclopride infused through the probe. For these experiments, samples 
were collected every 5 min. 
To measure increases in DA release, leptin (1 mg/kg, i.p.) or PBS (i.p.) was administered 
to the rat. After 3.5 hr, 30 min of baseline samples were collected and derivatized. A 4-port valve 
was used to switch to a solution of 40 µM cocaine. Samples were collected for 30 min with the 
cocaine infusion. A second switch was made on the 4-port valve to infuse 40 µM cocaine and 
100 µM raclopride through the probe. Samples were collected for another 30 min. Fractions were 




Figure 3.1: Changes extracellular dopamine 
measured after leptin injection. (A) 4 h after a leptin 
injection, there was no overall change in . (B) 
 decreased from 6.3 ± 1 nM prior to a leptin 
injection to 4.3 ± 1 nM 4 h after the leptin injection. 
When vehicle was injected, there was no change in 
(C)  or (D) . n=4, error bars show SEM. * 
indicates p ≤ 0.05. 
When comparing the average  or , paired t-tests were used to test for 
significance. Measurements were taken within the same animal before and after a leptin or PBS 
injection which warranted a paired vs. an unpaired t-test. For experiments where the relative 
changes of DA or its metabolites were plotted vs. time, statistical analysis was performed with a 
2-way repeated measure analysis of variance (ANOVA) using GraphPad Prism (GraphPad 
Software, Inc., La Jolla, CA). When significance was found in the time treatment interaction, the 





C6-DA in leptin treated 
rats 
 Acute leptin has been 
demonstrated to cause increases in both 
DAT and TH activity in vitro without 




further investigated how leptin affects 
basal DA concentrations with a more 
accurate sampling method (SIL 
microdialysis) and used rats as their 
own control. With infusion of 200 nM 
13
C6-DA through the microdialysis 
probe,  was calculated to be 0.26 ± 
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Figure 3.2: Changes in extracellular metabolite 
concentrations caused by leptin. (A) After a leptin 
injection there was no overall change in the 
[DOPAC]/[DA] ratio. The [3-MT]/[DA] ratio 
increased from and [HVA]/[DA] both increased 4 
h after a leptin injection. (B) There were no 
changes in the [Metabolite]/[DA] ratio 4 h after a 
vehicle injection. n=4, error bars show SEM. * 
indicates p ≤ 0.05.  
 
0.04 (n = 4) and 0.27 ± 0.02 before and after a 4 h leptin injection. For the control,  was 
calculated to be 0.27 ± 0.02 and 0.28 ± 0.02 (n = 4, Fig. 3.1) before and 4 h after a vehicle 
injection, respectively. , which can be used as an indirect measurement of DA uptake, did 
not change with leptin. DA uptake in the NAc is large enough such that the  is limited by 
diffusion across the membrane and 
increases in uptake cannot be measured with 
.
133, 143, 170
  remaining unchanged 
does not dispute previous studies where 
leptin was shown to increase uptake.
123
 
 With the  calculated and the 
extracellular concentration of endogenous 
DA measured,  could be calculated. 
Before the leptin injection,  was 6.3 ± 1 
nM and was reduced to 4.3 ± 1 nM (p ≤ 
0.05, paired t-test) 4 h after a leptin 
injection.  was calculated to be 7.6 ± 1 
nM before the vehicle and 7.7 ± 1 nM 4 h 
after the vehicle injection. Because  did 
not decrease 4 h after a PBS injection, we 
conclude that the reduction in  4 h after 
the leptin treatment was due to the leptin 
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Figure 3.3: D2 receptors were blocked after pretreatment with leptin or vehicle. (A) With the 
infusion of raclopride, DA had a large increase within 15 min in both leptin and vehicle treated rats. 
The maximum increase from raclopride (grey line) was 300 ± 60 % basal in the vehicle treated rats 
(filled circles) vs. 140 ± 10% basal in the leptin treated rats (open circles). (B) The leptin treated rats 
had an increase of 161 ± 10% basal DOPAC and vehicle treated rats had an increase of 118 ± 7 % 
basal. There were increases in the production of 3-MT (C) and HVA (D), but there were no 
differences between leptin and vehicle treated rats. n=4, error bars show SEM. * indicates p ≤ 0.05 
and ** indicates p ≤ 0.01.  
 
itself and not to extracellular DA concentrations changing over time. The reduction in basal DA 
following a leptin injection was small relative to the variability between animals, but detectable 
by using quantitative dialysis and within animal controls. Using an unpaired t-test with the same 
data, the decrease in  was not statistically significant decrease. The relative standard 
deviation of basal DA levels between rats and the small decrease in basal DA and not using 
quantitative microdialysis is most likely the cause of not seeing a decrease in basal DA in a 
previous study using the same procedure.
123
 By using quantitative microdialysis, which takes 
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into account  and probe variability, as well as using rats as their own control, we were able to 
measure a decrease in  within each animal after a leptin treatment. 
Endogenous metabolite changes with leptin  
With the UPLC-MS/MS method used for these experiments, the DA metabolites could be 
measured in addition to endogenous DA. 4 h following the leptin injection, the [3-MT]/[DA] 
ratio increased from 0.39 ± 0.01 to 0.54 ± 0.04 (n = 4, p ≤ 0.05) 3-MT, which is formed mainly 
in the extracellular space, has been used as an indicator for DA release.
171-174
 The [HVA]/[DA] 
ratio increased from 284 ± 20 to 408 ± 32 (p ≤ 0.05) following leptin injection. The 
[DOPAC]/[DA] ratio increased from 330 ± 44 to 381 ± 32 (Fig. 3.2). While not statistically 
significant, the leptin treatment showed a trend of increasing the [DOPAC]/[DA] ratio. DOPAC 
is mainly synthesized inside DA neurons.
175
 Thus, measuring extracellular 3-MT and DOPAC 
can provide a marker for the release and uptake of DA, respectively. The same measurements 
were taken before and 4 h after a vehicle injection. In these animals, no statistically significant 
differences in any of the [Metabolite]/[DA] ratios was measured. The increase in [3-MT]/[DA] 
and [HVA]/[DA] appears to be an effect of leptin rather than a change over time caused by the 4 
h time period between measurements. 
Raclopride infusion following leptin injection 
 To test the effect of autoreceptor regulation on extracellular DA concentrations, dialysis 
probes were infused with 100 µM raclopride, a D2 antagonist, 4 h after a leptin or vehicle 
injection. Raclopride evoked an increase in DA that peaked at 300 ± 80% (n = 5, Fig. 3.3) vs. 
164 ± 30% (n = 6) over baseline (p ≤ 0.01; comparison between increase with and without leptin) 
after vehicle and leptin injection. After the initial burst in DA, the vehicle treated rats maintained 
extracellular DA at 129 ± 5% of basal concentration and leptin treated rats maintained DA at 136 
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Figure 3.4: D2 receptors were blocked with uptake inhibited after pretreatment of leptin or vehicle. 
(A) After 20 µM cocaine infusion (black bar), there was no difference in DA increases between 
leptin (open circles) and vehicle (filled circles) treated rats. After the addition of 100 µM raclopride 
and 20 µM cocaine (grey bar), the increase in DA was greater in leptin treated rats indicative of 
greater DA release. (B) There were no differences in DOPAC measurements in leptin and vehicle 
treated rats. (C) When the [3-MT] was with cocaine is set to 100%, there is a 152 ± 18% increase in 
vehicle treated rats and 235 ± 24% increase in leptin treated rats. The inset shows the overall 
increase in % basal 3-MT. (D) There were no differences in HVA between leptin and vehicle 
treated rats with cocaine and with cocaine and raclopride. n=4 to 5, error bars show SEM. * 
indicates p ≤ 0.05 and ** indicates p ≤ 0.01. 
± 15% of basal concentration (no statistically significant difference). The attenuated extracellular 
DA increase is indicative of a lower tone on D2 receptors due to lower DA concentration with 
leptin. DOPAC increased 146 ± 7% during raclopride infusion with leptin and 112 ± 6% without 
leptin (p ≤ 0.01). The stunted release of DA with raclopride and leptin and the increase in 
DOPAC provides evidence that an increase in DA turnover and uptake is caused by leptin. After 
the raclopride infusion, 3-MT increased to 158 ± 12 % basal with leptin and 148 ± 6 % basal 
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Figure 3.5: Monitoring stable-isotope labeled metabolites after pretreatment of leptin. (A) There was 
no difference in the amount of 
13
C6-DA (grey bar) that diffused out of the probe before (filled circles) 
and after a leptin injection (open circles). (B) At the end of the 
13
C6-DA, there was a difference in 
13
C6-DOPAC production after leptin injection. (C) There were no differences in 
13
C6-3-MT 
production between after a leptin injection. (D) The % 
13
C6-HVA produced with leptin was larger 
compared to measurements taken prior to the leptin injection. n=4 to 5, error bars show SEM. * 
indicates p ≤ 0.05 and ** indicates p ≤ 0.01. 
with PBS. HVA increased slowly and reached a maximum of 147 ± 9 % basal and 139 ± 19 % 
basal with raclopride after the leptin and PBS injection, respectively. Neither the relative HVA 
nor relative 3-MT increases were statistically significant. 
Cocaine with raclopride infusion following leptin injection 
Leptin has been shown to increase TH levels in the NAc of ob/ob mice
163
 and increase 
TH activity and amphetamine stimulated DA release in the NAc compared to vehicle treated 
rats.
123
 The latter experiment also performed in vivo microdialysis and measured no differences 
in basal extracellular DA concentrations, which was hypothesized to be increased DAT activity 
and an increase in release due to the increased TH activity offsetting each other. The increase in 
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the [3-MT]/[DA] ratio we measured was indicative of an increase in release caused by leptin. To 
further test if DA release increased, cocaine followed by cocaine and raclopride were infused 
through the probe. Cocaine inhibited DA uptake and raclopride blocked the negative feedback of 
D2 receptors. With the cocaine infusion, the leptin treated rats had an increase in DA of 1130 ± 
150% basal (n = 5) while vehicle treated rats produced a 990 ± 150% basal increase (n = 4, Fig. 
3.4). No statistically significant differences with the cocaine infusion were measured, which is in 
agreement with a previous study in ob/ob and wild-type mice.
167
 Infusion of raclopride with 
cocaine was then administered to enhance release of DA with uptake blocked by cocaine. The 
DA increase in vehicle treated rats was 1390 ± 300 % basal vs. leptin treated rats, which had an 
increase of 2450 ± 270 % basal (p ≤ 0.05; comparison of % basal DA between leptin and vehicle 
treated rats). 
Differences in [3-MT] were also measured between leptin and vehicle treated rats during 
the cocaine and raclopride infusion. When comparing the change of [3-MT] relative to the [3-
MT] with cocaine (basal 3-MT set to 100% during cocaine infusion), the % increase in [3-MT] 
was 150 ± 17 % in PBS treated rats vs. 230 ± 20 % in leptin treated rats (p ≤ 0.05). No 
statistically significant difference was measured when comparing the overall increase (e.g. % 
basal measurements) of 3-MT after cocaine and raclopride infusion. During cocaine infusion, 
DOPAC decreased slightly to 96 ± 5 % basal and 94 ± 2 % basal with and without leptin, 
respectively. When cocaine was co-infused with raclopride, the DOPAC increased slightly to 
113 ± 4 % basal and 104 ± 10 % basal with and without leptin, respectively. No differences were 
detected in % basal HVA between leptin treated and PBS treated animals after a cocaine 
infusion. With cocaine and raclopride, HVA increased slightly to 110 ± 4 % basal and 106 ± 3 % 
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basal with leptin and with PBS treatment, respectively. No statistically significant differences in 




 To determine if changes in 3-MT, DOPAC, and HVA with leptin were caused by changes 
in enzyme activity, 
13







C6-HVA] were monitored. No differences were measured in 
the amount of 
13
C6-3-MT produced (refer to Fig. 3.5) from 
13
C6-DA prior to and after the leptin 




C6-HVA produced was an average of 24 ± 
7% (p ≤ 0.05) and 30 ± 8% (p ≤ 0.05) greater after the leptin injection. The change in the 13C6-
DOPAC was small but is consistent with greater DA uptake in leptin treated rats. 
Discussion 
Leptin increases DA uptake 
Several lines of evidence obtained here and elsewhere support the idea that acute leptin 
can decrease the extracellular DA concentration in the brain.
169
 Further, these studies suggest 
that this effect is caused by increased DAT activity rather than decreases in release or enhanced 
metabolism. 
The raclopride infusion revealed a lower increase in extracellular DA in leptin treated rats 
vs. vehicle treated rats. These changes could be due to a lower tone on D2 receptors, which may 
have caused a smaller increase in release. Another possibility is the increased uptake cleared the 
raclopride stimulated DA quicker in leptin treated rats. DOPAC, on the other hand, increased 





C6-DA following a leptin injection. Measuring DOPAC provides 
insight into the metabolic fate of DA. The DA that is taken up into the neuron is converted to 
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DOPAC or repackaged in vesicles. The lower release in DA after raclopride and the increase in 
DOPAC provided evidence that uptake increased due to a systemic leptin injection. 
The decrease in extracellular DA concentrations in the NAc may be one mechanism for 
how leptin modulates feeding behavior. Previous work has shown that increasing extracellular 
DA in this brain region increases the incentive salience of sucrose.
26
 In food deprived rats, basal 
extracellular DA concentrations decreased and feeding stimulated DA was attenuated  in the 
NAc in rats that received leptin vs. vehicle.
169
 If leptin can decrease extracellular DA and 
decrease the amount of DA released during feeding, the incentive salience of food should be 
decreased. Our study used a more accurate method than uncalibrated microdialysis and further 
showed that extracellular DA concentrations decreased in rats fed ad libitum after a leptin 
treatment. The cause of this decrease was demonstrated to be likely due to an increase in DAT 
activity. Leptin increasing DA uptake may cause the overall DA tone to decrease along with food 
induced increases in extracellular DA. Leptin would then restrict feeding by decreasing the 
reward value of food. 
Leptin increases DA release 
 Although leptin reduces the DA concentration, our group and others have shown that it 
can increase TH activity. We sought to better understand how this might affect DA concentration 
and dynamics. The increased [3-MT]/[DA] ratio after a leptin injection with no difference in 
13
C6-3-MT production from 
13
C6-DA provided evidence that a greater amount of DA was being 
released with no change in COMT activity. Additionally, the infusion of raclopride with uptake 
blocked by cocaine caused a larger increase in extracellular DA in leptin treated rats vs. vehicle 
treated rats. These experiments provide evidence that DA release was increased in the NAc 
following a leptin injection. 
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 The increased DA release caused by leptin appears to be minor. The cocaine infusion on 
its own produced no differences between leptin and vehicle treated rats. Our results are in 
agreement with a previous study with ob/ob and wild-type mice where no differences were 
detected in the cocaine induced DA release in the NAc,
167
 even with more TH present in wild-
type mice.
163
 The small increase in release was only measured in our study with raclopride + 
cocaine infusion following cocaine alone. The small effect on release with the greater effect on 
uptake netted a decreased  of DA in the NAc. Nevertheless, leptin does appear to play a role 
in affecting multiple processes in the DA system which ultimately allows it to modulate feeding 
behavior. 
Conclusion 
Changes in basal extracellular DA concentrations caused by leptin in rats fed ad libitum 
has not been previously reported. Our study used a quantitative microdialysis technique with rats 
as their own control to demonstrate the net effects of leptin on DA in the NAc. By infusing 
raclopride through the probe, the cause of the net decrease was shown to be an increase in 
uptake. The infusion of cocaine and raclopride revealed an increase in DA release caused by 
leptin, although it appears to be minor. The ability to understand how leptin modulates the DA 





Evidence for compartmentalization of extracellular glutamate in vivo 
 
Introduction 
Glutamate (Glu) is the primary excitatory neurotransmitter in the brain, yet its acceptance 
as a neurotransmitter was slowed by the observation that it is ubiquitous, seeming to preclude its 
ability to act as a selective messenger molecule. It is now thought that highly active reuptake and 
possibly compartmentalization, e.g. of the synapse from the rest of the brain extracellular space, 
facilitates Glu signaling. Understanding of Glu signaling and operation of different 
compartments has continued to evolve based on improved images of synapses, modeling, and 
direct chemical measurements. The role of glial cells in particular seems to be important shaping 
Glu signaling. A common view is that Glu neurotransmission is facilitated by a tripartite synapse 
consisting of presynaptic neuron, postsynaptic neuron, and astrocyte.
45, 176, 177
 In this view, 
neurons release neurotransmitter into a synaptic cleft raising the concentration to 1.1 mM in a 
few ms.
178
 The concentration is rapidly reduced by diffusion away and reuptake by excitatory 
amino-acid transporters (EAAT). Astrocytes are critical in this regard because they provide 
barriers to diffusion and contain ~90% of the EAAT.
179
 Spill-over is common, but on a small 
scale (1-10%). The astrocytes may also release Glu and other neuromodulators by a variety of 
mechanisms. Such release may be to maintain Glu tone, modulate neurotransmission, or send 
signals to more distant synapses.
42, 45, 180
 Astrocytes also support neurons by providing a source 
of Glu via the Glu-glutamine (Gln) shuttle. Glu that is taken up by glia
181
 can be converted to
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Gln by glutamine synthase. This Gln is released and can be taken back up by neurons where it is 
converted to Glu by glutaminase, an enzyme localized primarily in neurons. In this way it is 
thought that glial cells maintain a supply of neuronal Glu for signaling.
182-186
 Astrocytes may 
also help couple neurotransmission to metabolism by connection to blood vessels.
187, 188
 
Within this framework a number of controversial issues have arisen. One relates to 
extracellular Glu concentration and its primary sources. Electrophysiological measurements in 
hippocampal slices yield estimates of ~25 nM for Glu.
85, 189
 On the other hand, in vivo 
measurements in the extracellular space by microdialysis show a higher concentration of 1-10 
uM.
68, 170
 This “basal” concentration appears to contain little Glu that was directly released by 
neurons. This conclusion is based on the finding that it is unaffected by blocking sodium 
channels with TTX.
190, 191
 Rather, evidence suggests that this extracellular Glu is released from 
astrocytes by a variety of mechanisms including Cys-Glu antiporter,
192
 and vesicular release by 
activation of voltage-dependent calcium channel.
44
 It is concluded from these observations that 
little Glu escapes the synapse under basal conditions.
41, 124
 Studies using another invasive probe 
technique, enzyme electrode sensors, have reported somewhat higher concentrations that can be 
reduced by ~40% by microinjection of TTX near the electrode.
79, 80
 An interpretation of these 
observations is that Glu does escape the synapse at appreciable concentrations to enable 
detection.  
While the basal Glu measured by microdialysis is not regulated as expected for neuronal 
release, under some conditions a change in extracellular Glu can be elicited that appears to 
directly relate to neuronal activity.
193-195
 Electrical stimulation evoked release that was blocked 
by TTX and regulated by autoreceptors
193
 and stress has increased glutamate in the cortex that is 
TTX sensitive.
194, 195
 Combined, these results indicate that at least in some brain regions under 
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some conditions neuronal release can be detected in extracellular space. While such release may 
be direct spillover from the synapse, it has also been proposed that they represent active release 
by astrocytes in response to being stimulated by neuronal Glu.
196
  
A number of explanations have been put forth to explain the discrepancies in 
concentrations and sources of extracellular Glu. Experimental artifacts may contribute to these 
differences. It has been suggested that tissue damage caused by invasive probes results in falsely 
high concentrations.
85, 189
 This argument is bolstered by the observation that if the concentration 
was 1-30 uM, then the concentration would be close to excitoxic levels and receptors would be 
desensitized. Tissue damage has also been invoked to explain why electrochemical sensors give 
a higher concentration than dialysis probes.
197
 Another view that has been proposed is that 
compartmentalization between the synapse, perisynapse, and extracellular space, enforced by 
spatial distribution of release and reuptake sites, allows for differences in concentration among 
these regions in vivo.
198
 According to this view, the different techniques are measuring from 
different pools based on the nature of the technique. This view accommodates roles for neuronal 
and astrocytic release in Glu transmission. While attractive, evidence that multiple extracellular 
pools or compartments actually exist in vivo is lacking. One issue has been the difficulty of using 
a single technique that allows distinction of a neuronal pool separate from an astrocytic pool. 
Another issue relates to the necessity and timing of the Glu-Gln shuttle for maintaining 
Glu signaling. The Glu-Gln shuttle is well-established. Its significance has been bolstered by the 
observation that effects of Glu transmission can be blocked by inhibiting the conversion of Gln 
to Glu.
182-184, 186, 199
 The recent observation of rapid fluctuations in Gln during neuronal activity 
also seem to support the importance of Gln for moment to moment Glu signaling.
200
 At the same 
time, modulation of Glu neurotransmission by Gln has been difficult to observe. For example, in 
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rat hippocampus slices, Gln applied at high concentrations (4 mM) had no effect on the quantal 
amplitude or frequency of somatic whole-cell voltage-clamp recordings for up to 4 h.
201
   
In this report, we use microdialysis and stable isotope metabolic labeling to distinguish 
different pools of Glu in vivo. We reason that if 
13
C5-Gln was delivered to the brain, it would 
form 
13
C5-Glu mainly in neurons. Neuronal release and collection of this 
13
C5-Glu would in turn 
allow measurement of neuronally derived Glu despite a high background of Glu from non-
neuronal sources normally detected. We find that the 
13
C5-Glu is detected and is regulated 
differently from the endogenous or background 
12
C-Glu. These results suggest two different 
compartments, one is primarily neuronal while the other is not, can be accessed in vivo. The 
results also suggest that spill-over can occur leading to potential for neuronal communication to 
astrocytes. Finally, the results support the idea that that Gln-Glu cycling is rapid with newly 
formed Glu being readily released by neurons. 
Methods 
Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise noted. Artificial cerebral spinal fluid (aCSF) comprised of 145 mM NaCl, 2.68 mM 
KCl, 1.01 mM MgSO4, 1.22 mM CaCl2, 1.55 mM Na2HPO4, 0.45 mM NaH2PO4 (Fisher 
Scientific, Pittsburgh, PA). 
13
C5-Glu was purchased from Cambridge Isotopes (Andover, MA). 
Mobile phase of the LC column included 10 mM ammonium formate and 0.15% formic acid. 
Microdialysis probes 
Probes were constructed as previously described.
149
 Briefly, 40/100 µm (i.d./o.d.) fused 
silica capillaries (Polymicro Technologies, Phoenix, AZ) were glued side-by-side with a 2 mm 
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offset. The capillaries were ensheathed in a regenerated cellulose membrane with both ends 
sealed by polyimide sealing resin (Grace, Deerfield, IL). The flow rate through the probe was set 
to 1 µL/min. 
Sample derivatization and analysis 
Each sample was derivatized with benzoyl chloride and analyzed as described 
previously.
68
 Briefly, samples were sequentially mixed with 100 mM sodium tetraborate, 
benzoyl chloride (2% in acetonitrile, v/v), and internal standard in a 2:1:1:1 ratio. Internal 
standard comprised of standards reacted with 
13
C6-benzoyl chloride in 100 mM sodium 
tetraborate. The internal standard was the diluted 1:100 in DMSO and 1% formic acid (v/v). The 
samples were analyzed on a Waters UPLC system with a Waters HSS T3 column (1 mm x 100 
mm, 1.8 µm). A Waters/Micromass Quattro Ultimatriple quadrupole or an Agilent 6410 triple 
quadrupole mass spectrometer was used for detection. Mobile phase A was 10 mM ammonium 
formate and 0.15% (v/v) formic acid in water. Mobile phase B was acetonitrile. The peak areas 
of each analyte were divided by the area of the internal standard.  
Surgery 
Male Sprague-Dawley rats were anesthetized with ketamine (65 mg/kg, Fort Dodge 
Animal Health, Fort Dodge, IA) and dexdomitor (0.25 mg/kg, Pfizer Animal Health, New York, 
NY) and placed in a stereotaxic frame. A burr hole was drilled where the probe was being 
implanted (+0.2 A/P, ±2.3 L, aimed at cortex).
150
 The rats were bi-laterally implanted. Additional 
burr holes were drilled for skull screws to hold the cap in place. The probes were lowered 3 mm 
from the top of the skull and dental cement (A-M Systems, Inc., Sequim, WA) was used to hold 
the probes in place. All animal procedures were approved by the University Committee for the 
Use and Care of Animals at the University of Michigan. 
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The day of the experiment, rats were lightly antethetized in an isofluorane drop box. The 
microdialysis probes were attached to the syringes and perfused with aCSF at a flow rate of 1 
µL/min. The rat was tethered to a Raturn (Bioanalytical Systems, Inc., West Lafayette, IN).  
Measuring 
13
C5-Glu production with 14 min plug of 
13
C5-Gln 
 Syringes containing aCSF or a pharmacological agent were switched to a syringe 
containing 2.5 µM 
13
C5-Gln and aCSF or a pharmacological agent using a 4-port valve (Valco 
Instruments, Houston, TX). The pharmacological agents administered were 2 µM tetrodotoxin 
(TTX), 200 µM (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylate (ACPD), or 200 µM (RS)-α-
Methyl-4-carboxyphenylglycine (MCPG, Tocris, Bristol, UK). If TTX, ACPD, or MCPG were 
tested, they were perfused for 15 min prior to the 
13
C5-Gln switch and were also present during 
the 
13
C5-Gln infusion. For the 1 mM L-trans-Pyrrolidine-2,4-dicarboxylic acid (PDC, Tocris) 
aCSF was perfused and the PDC was perfused only during the 
13
C5-Gln perfusion. Samples were 
collected every 2 min and derivatized. 
Measuring effect of longer infusion of 
13
C5-Gln 
 For the tail pinch, a syringe containing 2.5 µM 
13
C5-Gln with and without 2 µM TTX was 
switched to the probe for 10 min prior to the baseline collection. After 3 baseline fractions, a 
binder clip was attached to the rat for 10 min. The clip was removed and collections continued 
for an additional 14 min. Fractions were collected every 2 min. To test the TTX sensitivity of 
the 
13
C5-Glu over a longer period, 2.5 µM 
13
C5-Gln was infused through the probe for 60 min. At 
60 min, the syringes were switched with the 4-port valve to a solution containing 2.5 µM 
13
C5-




Figure 4.1: Multiple infusions of 
13
C5-Gln as a control. (A) There were no differences in the 
13
C5-
Glu produced from 2 consecutive infusions of 
13
C5-Gln (grey bar). (B) The amount of 
13
C5-Gln 
measured between 2 consecutive infusions was the same. (C) There is no effect of 2 µM 
13
C5-Gln 
on the concentration of 
12
C-Glu or on (D) 
12
C-Gln. 
For comparison of individual time points for 
13
C5-Glu produced with different drug 
treatments, paired t-tests were performed. When comparing the 
13
C5-Glu production with aCSF 
vs. drug treatment, a linear mixed model regression was used to test significance. SPSS (IBM, 
Armonk, NY) was used for the mixed model regression. The rat ID was used as the subject, drug 
treatment was used as a factor, time was used as a covariate, and the measurement (e.g. % basal) 
was tested as the dependent variable. 
Results.  
Concentration of Glu and Gln in the brain extracellular space. 
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Figure 4.2: Tetrodotoxin provided evidence for neuronal 
13
C5-Glu production. (A) With the infusion 
of 2 µM TTX (black bar), the [
13
C-Glu]out was reduced (open circle) compared to aCSF infusion 
(filled circle). (B) There was no change in the [
13





C-Glu]out did not change when TTX was infused. 
 In vivo calibration of a microdialysis probe is useful to correct for probe recovery and 
effects of brain tissue on transport within the brain to the microdialysis probe. One method of in 
vivo calibration is to infuse a stable isotope labeled (SIL) form of a compound and measure its 
loss from the microdialysis probe.
135, 136, 170
 This loss is used to calculate the extraction fraction 










C5-Glu that is tetrodotoxin sensitive. 
(A) When 
13
C-Gln was infused for 60 min (grey 
bar), there was no drift in the [
13
C5-Glu] (open 
circle) produced. After the 60 min 
13
C5-Gln 
infusion, TTX reduced the 
13
C5-Glu produced. 
There was no TTX sensitivity in the 
12
C-Glu 
(filled circle). (B) There was no change in [
13
C-
Gln]out (open circle) nor [
12
C-Gln]out (closed 
circle) with TTX infusion.  
In the above equation,  and are the concentration of SIL compound that is measured at 
the outlet of the probe infused into the probe, respectively. The apparent concentration (Capp) of 
the compound in the brain can be measured with the following equation: 
 
where ( ) is the measured concentration of endogenous compound in dialysate. Using 
this method, we calculated that probe 
recovery was 0.30 ± 0.03 for Gln and 0.29 ± 
0.01 for Glu while infusing 2.5 µM and 5.0 
µM of Gln and Glu respectively. The Capp of 
Gln = 179 ± 20 µM and Glu = 9.4 + 0.6 µM 
(n=11). These values were in good 
agreement with previous microdialysis and 




Gln is rapidly converted to Glu in the brain 
Infusing 2.5 µM 
13
C5-Gln through 
the probe resulted in a loss of 
13
C5-Gln due 
to diffusion into the brain so that the 
concentration in dialysate exiting the probe 
was 1.74 ± 0.07 uM (n = 11). During 
infusion of 
13
C5-Gln, we also found that 
13
C5-Glu was collected. The 
13
C5-Glu reached a steady state concentration within 1 min of 
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Figure 4.4: Metabotropic glutamate receptor regulation of 
13
C5-Glu. (A) With the infusion of 
200 µM ACPD (black bar), the [
13
C-Glu]out (open circle) was decreased compared to [13C5-
Glu]out with aCSF (filled circle) during the infusion of 
13
C5-Gln (black line). (B) There was no 
significant change in the [
13
C-Gln]out with the infusion of ACPD. (C) [
12
C-Glu]out and (D) [
12
C-
Gln]out did not have a significant change when ACPD was infused. (E) When ACPD and MCPG 
were combined, [
13
C-Glu]out did not decrease. (F) There was no change in [
13
C-Gln]out with both 
ACPD and MCPG.  
starting 
13
C5-Gln perfusion (data not shown). The recovered 
13
C5-Glu was 60 ± 7 nM (n = 9 
animals) and stayed stable for up to 60 min, the longest time tested. Once 
13
C5-Gln was removed 
from the probe, the 
13
C5-Glu signal declined to near baseline in the next fraction suggesting rapid 
dissipation, either by diffusion or metabolism or both, of the labeled Glu. The concentration of 
13
C5-Gln added to brain and 
13
C5-Glu recovered were low, less than 1%, compared to their 
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Figure 4.5: Concentration dependence of 
13
C5-Gln 
on metabotropic glutamate receptor antagonist on 
13
C5-Glu production. With the infusion of (A) 2.5 µM 
13
C5-Gln (solid grey bar), (B) 15 µM 
13
C5-Gln 
(dashed grey bar), and (C) 150 µM 
13
C5-Gln (dotted 
grey bar), the greatest increase in 
13
C5-Glu with the 
infusion of 200 µM MCPG (black bar) compared to 
aCSF was the 15 µM 
13
C5-Gln infusion. The 150 µM 
13
C5-Gln infusion produced no increase in 
13
C5-Glu. 
estimated in vivo concentrations. This 
concentration appeared to be low enough 
to not cause irreversible or unexpected 
effects. For example, infusion of Gln did 
not affect endogenous concentrations of 
Gln or Glu and the concentration of 
13
C5-
Glu produced from 
13
C5-Gln was 
unchanged between multiple infusions in 
the same rat (Fig. 4.1). 
13
C5-Glu concentration is regulated by 
TTX and autoreceptors 
Gln is mainly converted to Glu in 
neurons; therefore to reach the probe 
13
C5-
Glu must have been released by neurons. 
We asked if the 
13
C5-Glu that was detected 
was modified by treatments that would be 
expected to modify neuronal release. 
Infusion of 2 µM TTX prior to and during 
13
C5-Gln infusion (Fig. 4.2) suppressed 
release of 
13
C5-Glu by 62 ± 7% (p ≤ 
0.001). Use of a higher concentration of 
TTX (50 uM) did not further reduce 
13
C5-Glu concentration. If TTX was applied 60 min after 
beginning 
13
C5-Gln infusion (Fig. 4.3), the 
13
C5-Glu was still reduced but by just 34 ± 3% (p ≤ 
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Figure 4.6: Effect of PDC on endogenous and 
13
C5-Glu extracellular concentrations. (A) With the 
infusion of 1 mM PDC (black bar), [
13
C-Glu] (open circle) increased to 173 ± 8% relative to no 
PDC (closed circle) with the infusion of 2.5 µM 
13
C-Gln (black bar). (B) PDC had no effect on the 
loss of 
13
C-Gln through the probe membrane. (C) PDC increased [
12
C-Glu] by 342 ± 76% relative 
to no PDC perfused through the probe. (D) PDC had no effect on [
12
C-Gln]. Error bars show SEM, 
n=4. *** indicates p ≤ 0.001, ** indicates p ≤ 0.01, and * indicates p ≤ 0.05. 
0.001). No statistically significant difference was measured between the 62% reduction of the 
short 
13
C6-Gln infusion vs. the 34% reduction in the longer 
13





C-Glu was unchanged by TTX treatment (Fig. 4.2). This latter result is in 
agreement with numerous studies that have found little effect or even increases in dialysate Glu 
with local TTX treatment.
124, 202
  
Neuronal Glu release is also modulated by mGluR. In previous studies, group II mGluR 
agonists have decreased Glu in the hippocampus
203
 and nucleus accumbens when infused 
through the probe;
204
 however, other studies have shown that infusion of group I and II mGluR 
agonists and antagonists infused through microdialysis probes have no effect on basal Glu 
measured by microdialysis
12, 205, 206
. We found no effect on basal concentrations of endogenous 
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Glu (and Gln) following infusion of 200 µM ACPD (group I and II mGluR agonist) and 200 µM 
MCPG (group I and II mGluR antagonist). In contrast, the 
13
C5-Glu detected was reduced by 59 
± 9% (p ≤ 0.001) by ACDP (Fig. 4.4). This effect was blocked by simultaneous infusion of 200 
µM MCPG with the ACDP. MCPG infusion alone increased 
13
C5-Glu to 124 ± 17% of baseline 
when 2.5 µM 
13
C5-Gln (n = 3) was infused through the probe. To determine if the small increase 
was due to the [
13
C5-Glu] not being large enough to activate the group I and II mGluR 
autoreceptors, 15 and 150 µM 
13
C5-Gln was infused into the probe with and without 200 µM 
MCPG (Fig. 4.5). The infusion of 15 µM 
13
C5-Gln produced 690 nM 
13
C5-Glu in the dialysate 
which was increased 140 ± 30% in the presence of MCPG (p ≤ 0.05, n = 3). These results are 
consistent with autoreceptor regulation of the 
13
C5-Glu that is collected by the dialysis probe. 
13
C5-Glu produced from 150 µM 
13
C5-Gln infused through the probe did not increase with 
MCPG (n=4).  
Effect of Gln Concentration on Glu 
While most experiments infused 2.5 µM Gln, we also evaluated the dependency of Glu 
on the concentration of Gln infused. Infusing Glu up to 150 µM produced a linear concentration 
of 
13
C5-Glu. At a higher concentration (50 µM 
13
C5-Gln in, 14 min infusion), the 
13
C5-Glu Glu 
was not TTX sensitive. 
Uptake inhibition 
PDC is a transportable Glu uptake inhibitor that significantly raises extracellular Glu 
concentration by both blocking reuptake and by being exchanged with intracellular Glu.
131, 207
 
Addition of 1 mM PDC to the dialysis perfusion fluid while 
13
C5-Gln was also infused increased 
12
C-Glu 342 ± 76% and 
13
C5-Glu 173 ± 8% (p ≤ 0.01) relative to that without PDC (Fig. 4.6). 
PDC did not affect 
13
C5-Gln or endogenous Gln. 
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Figure 4.7: Increased 
13
C5-Glu after tail pinch. (A) [
13
C5-Glu]out (filled circle) increased 155 ± 14% 
when a clip was applied to the rats’ tails (grey bar). TTX (black bar) blocked the increase in [
13
C5-
Glu]out (open circle) during the pinch. (B) [
13
C-Gln]out did not change during the course of the tail 
pinch. No changes in (C) [
12
C-Glu]out or (D) [
12
C-Gln]out were measured. Error bars show SEM, n=3-4. 
*** indicates p ≤ 0.001, ** indicates p ≤ 0.01, and * indicates p ≤ 0.05. 
Stimulated release of Glu 
  Stressors such as tail pinch have previously been reported to increase extracellular Glu 
in the cortex as measured by microdialysis and sensors.
79, 80, 194
 Interestingly, this observation has 
not been widely reported and others have found that a stress response is highly variable.
190
 In our 
hands, tail pinch had no effect on endogenous 
12
C-Glu (Fig. 4.7C) or 
12
C-Gln. However, tail 
pinch did increase 
13
C5-Glu following infusion of 
13
C5-Gln by 155 ±14% (p ≤ 0.05) (Fig. 4.7A). 
This increase was completely abolished by TTX infusion (p ≤ 0.05).  
Discussion 
13
C5-Glu is from neurons  
77 
 
Our objective in perfusing 
13
C5-Gln was to use the Glu-Gln shuttle to isolate a neuronal 
component of Glu in the extracellular space that could be monitored by endogenous 
measurements alone. Here we uncover a TTX-sensitive extracellular compartment of Glu that is 
apparent under “basal conditions”, e.g. without specific behavioral, drug, or electrical activation 
of neurons. The Glu is derived from 
13
C5-Gln added exogenously at low concentrations. Because 
neurons preferentially convert Gln to Glu in the brain, a majority of this 
13
C5-Glu must be 
released from neurons. Supporting the idea that it derives from neurons, we find that it is 
strongly inhibited by activation of group I and II mGluR, an effect blocked by antagonists, and 
increased by antagonists. We interpret this as modest neuronal overflow under basal conditions 
under some control by autoreceptors. In contrast, the endogenous 
12
C-Glu is completely 
unaffected by these treatments. We conclude, like others, that the endogenous 
12
C-Glu must have 




C glu are coming from different extracellular sources, 
one primarily neuronal (
13
C) and the other primarily non-neuronal (
12
C). These results show that 
the use of 
13
C5-Gln allows effective probing of neuronally derived Glu while the endogenous Glu 








C-Glu found here is perhaps 
surprising. If Glu can normally escape from the synapse, then the basal concentration of 
endogenous, 
12
C-glu should be at least partially TTX/ACPD sensitive; however, it is not.  
We believe that this discrepancy may be because the 
13
C5-Glu that is detected is formed 
recently. 
13
C5-Glu appears no more than 60 s after the 
13
C5-Gln is added and is eliminated as 
soon as the 
13
C5-Gln is removed. The rapid clearance of 
13
C5-Glu from the extracellular space 
means that the 
13
C5-Glu detected in any fraction was recently formed and therefore unlikely to be 
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significantly mixed with other compartments. In effect, the rapid flux of Glu allows the 
13
C-
labeled form to fill an “empty” pool making it readily detected. In contrast, 
12
C-Glu detected 
could be coming from multiple sources. As a result, the percentage that is coming directly from 
neurons must be lower. Judging by the insensitivity to TTX, only a very low percentage is 
directly from a neuron. 
A second reason is spatial distribution of the possible sources of Glu. The 
13
C5-Glu 
detected must have been formed primarily near the probe surface and therefore has a minimal 
distance to diffuse to the probe. This would lessen the likelihood of being captured by 
transporters or other elimination mechanisms. In contrast, 
12
C-Glu may be formed from both 
close and farther away allowing for the possibility that astrocytic release or other homeostatic 
mechanisms would dominate. 
When 50 µM 
13
C5-Gln was infused through the probe for 14 min, 
13
C5-Glu did not 
decrease with the infusion of TTX. While a 64% decrease was measured with a 14 min infusion 
of 2.5 µM 
13
C5-Gln, longer infusion times of 2.5 µM 
13
C5-Gln caused less TTX sensitivity. 
Higher concentrations of 
13
C5-Gln infused and longer infusions may cause the more concentrated 
13
C5-Glu to reach compartments available to the astrocytes, which may cycle into the glutamate 
pool normally measured by microdialysis. We do not believe that the detection of 
13
C5-Glu is an 
artifact due to altering or saturating normal Gln/Glu processing. The 
13
C5-Gln concentration 
exiting the probe was 760 ± 70 nM. This concentration would be the maximal possible added to 
the brain and therefore much lower than the 50 ± 4 µM endogenous that we measured. Similarly, 
the concentration of 
13
C5-Glu recovered was 60 ± 7 nM, much less than the endogenous Glu 





 The situation for Glu is different from most other neurotransmitters. 
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Neuronal Glu is dependent on a supply of Gln and even moment-to-moment changes in Gln are 
believed to occur
200
. This strong metabolic dependency of Glu makes it more susceptible to 
disturbance by depletion than other neurotransmitters. Interestingly, our observation is in 
contrast to that observed in hippocampal slices where it was found that exogenous Gln did not 
affect Glu signaling until 4 h after exposure leading to the conclusion that in that environment 
the neurons do not depend upon astrocytic Gln, at least for moment to moment signaling.
201
  
Differentiation of stimuli 
The use of the 
13
C5-Gln allows differentiation of how perturbations modulate different 
sources of Glu. Our results show that a stress stimulus, tail-pinch, evokes release of 
13
C5-Glu and 
that the release is blocked by TTX. In contrast the 
12
C-Glu was relatively unaffected. We 
conclude that the Glu released is due to neuronal activation with little response or modulation by 
astrocytes. A few previous studies have shown that this stimulus can evoke release of 
endogenous Glu although we could not replicate that finding.
79, 80, 194, 208
 One of the studies was 
based on electrochemical sensing, which may have a different ability to detect neuronal Glu. The 
microdialysis study showed that Glu release is dependent on conditions, for example a second 
tail pinch gives much reduced release.
208
 Therefore the state and prior stress of the animal may 
influence detection of Glu. Also, technical issues may influence ability to recover a neuronally 
derived Glu signal.  
PDC is a transportable inhibitor and therefore could affect extracellular Glu in two ways. 
One is to allow spread of Glu released from neurons or glial cells. A second action is release of 
Glu due to exchange of drug for intracellular Glu. Since Glu is primarily taken up by glial cells, 
we would expect that the exchange mechanism would cause glial cell release. In agreement with 
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C-Glu with PDC treatment. 
The 
12
C-Glu increased 342 ± 76% baseline and 
13
C5-Glu increased 173 ± 8% compared to aCSF.  
Implications 
These results provide strong evidence of at least two, differentially regulated sources for 
glu within the brain extracellular space. One source is detected as endogenous Glu and is likely 
due primarily to astrocytic release. The other source is detected as 
13
C5-Glu derived from Gln 
and appears to be released from neurons. Detection of 
13
C5-Glu suggests that it can “leak” from 
synapses and therefore must intermingle with the other pool in the extracellular space where the 
endogenous 
12
C-Glu is found. The clear distinction in sources and regulation of Glu supports the 
concept of a compartmentalized Glu. Glu from neurons is released from synapses and possibly 
ectopic synapses generating a concentration that dependent upon the local environment. The 
other source, for example astrocytes, is releasing Glu with a different regulation and in a 
different space.  
The ability to neuronal release of Glu without any stimulation by merely adding a small 
amount of Gln also supports the idea that Glu neurons in the vicinity of the probe are functional 
in the sense that they take up Gln, convert it to Glu, and release it in a TTX-sensitive and mGluR 
modulated manner. Thus, despite the physical trauma of probe insertion, the probe is able to 
monitor regulated Glu neurotransmitter release as established for other neurotransmitters.  
The relatively high concentration of Glu detected by microdialysis and sensors has been 
suggested to be an artifact
85
, despite identification of reasonable sources such as the Cys-Glu 
antiporter
42
. Our results show that despite the concentration measured, autoreceptors are not 
normally activated since MCPG did not affect release by itself. These receptors are functional 
because their activation suppressed the neuronal component and this effect was blocked by 
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MCPG. This result also supports compartmentalization since the receptor regulation for the 
different sources is different. 
The results also support the idea that Glu-neurons are dependent upon the Glu-Gln shuttle 
to maintain a supply of Glu for release
49, 50
. Indeed, the 
13
C5-Glu was released within 1 min of 
supplying 
13
C5-Gln showing that this new Glu rapidly put to use by neurons for signaling. The 
ready manipulation of Glu levels by Gln suggests that this may be a route for astrocytes to 
influence neuronal signaling. That is, changes in metabolic conversion of Glu to Gln or release 
of Gln would manipulate Glu signaling.  
Released Glu is known to be taken up by glial cells. Interesting, once the Gln is removed, 
the 
13
C5-Glu was immediately depleted. Therefore, multiple fates for glu taken up by glial cells 
must exist. These include metabolic conversion to α-ketoglutarate
188
 or converted back to 
13
C5-
Gln. Due to the large concentration of 
12
C-Gln in the extracellular space vs. the low 
concentrations of 
13
C5-Glu produced in these experiments, the converted 
13
C5-Gln would be 
released by the astrocyte at relatively low concentrations. 
In this study, we have successfully shown evidence for the compartmentalization of Glu 
production limited mainly to neurons. With 
13
C5-Gln, we showed evidence through activating 
mGluR 2/3 receptors and using TTX that the production of 
13
C5-Glu was neuronally derived. We 
also showed that increases in 
13





Conclusions and future directions 
 
Measuring neurochemical changes from an intact brain can provide insight into many 
neural functions including memory, learning, mental diseases, and cognition. Microdialysis is the 
workhorse of sampling methods to study the central nervous system. The small size of the probes 
and the large amount of analytical techniques available to analyze dialysate samples makes 
microdialysis a versatile, robust method. A large drawback to this method is the lack of 
quantification with uncalibrated microdialysis. Without in vivo calibration, only relative changes 
can be measured and not absolute concentrations. Absolute concentrations may be important for 
setting the tone or endogenous exposure of receptors to neurotransmitter under basal conditions. 
Further, in vivo calibration of microdialysis provides the in vivo recovery which provides 
additional information on the in vivo environment. In particular, in vivo recovery and extraction 
fraction can be useful in discerning how neurotransmitter mass transport is affected by active 
processes such as reuptake and metabolism. In this work, a novel approach to quantitative 
microdialysis was developed based on infusion of stable isotope labeled neurotransmitter and 
then applied to the measurement of DA and Glu under different conditions. It is shown that the 
calibrated method is efficient relative to other calibration methods and provides novel insights 




Uncalibrated microdialysis is only able to provide a subset of information available with 
quantitative microdialysis. For example, decreased uptake caused a decrease in Ed for both DA 
and Glu when measured using NNF.
126, 131
 By measuring Ed and monitoring changes in DA or 
Glu concentrations, it was possible to determine the source of increases (increased release or 
decreased uptake) in extracellular DA and Glu concentrations.
133
 In addition to DA and Glu 
studies, accounting for differences in uptake has proven useful in serotonin transporter (SERT) 
knockout mice. Uncalibrated microdialysis showed no differences in Capp between the wild-type 
and heterozygous knockout, which had a 50% reduction in SERT gene expression. After 
quantitative microdialysis, basal [5-HT] was indeed higher in the heterozygous knockout.
145
 
 The main problem with employing quantitative microdialysis techniques is the large 
amount of time or animals required for each calibrated measurement. NNF measurements can 
take up to 7 hr per subject to obtain calibrated measurements.
131
 dNNF requires less time per 
animal but requires at least 3x more animals for each experiment.
133
 
The SIL microdialysis technique demonstrated in this work can be performed on the 
same timescale and with the same number of subjects as uncalibrated microdialysis because 
extraction fraction is measured on every sample of every animal. In our study, SIL microdialysis 
measurements of Capp and Ed for Glu and DA matched the same values within 10% when 
measured with NNF. With uptake blockers,  was shown to decrease by 30% and 35% with 
the local infusion of 5 µM nomifensine and systemic injection of cocaine (20 mg/kg, i.p.), 
respectively. With the local infusion of Glu uptake inhibitor PDC,  decreased by 40%. These 
decreases in Ed effectively caused Capp for both DA and Glu to be undervalued by as much as 
50%. These results illustrate the potential of the SIL method to provide information on tissue 
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effects (e.g. changes in uptake) and avoid artifacts due to such changes during dynamic 
measurements.  
 In addition to the calibrated concentration and tissue effects measured with SIL 
microdialysis, the SIL method also provides the opportunity to monitor metabolism and flux of 
neurotransmitters by recovering and measuring SIL metabolites. Measuring the metabolism of 
SIL neurotransmitters is especially useful for measuring neuronally derived Glu. Because Glu is 
released from both neurons and astrocytes, trying to differentiate the two sources is difficult. By 
infusing 
13
C5-Gln through the probe, newly formed 
13
C5-Glu can be measured. The enzyme 
responsible for the conversion of Gln to Glu, glutaminase, is preferentially located within the 
neuron. The newly formed 
13
C5-Glu is ACPD and TTX sensitive and increases with a tail pinch. 
These findings suggest that it is neuronally derived. TTX sensitivity of basal Glu has been 
measured with electrodes
41, 80, 209
, but has not previously been measured with microdialysis.
124
 
Measuring neuronally derived extracellular Glu with SIL microdialysis can be used to the Glu 
system in models for stress, disease, and addiction, which has been severely limited with 
uncalibrated microdialysis.  
Along with monitoring metabolism in the Glu-Gln cycle, SIL microdialysis can be used 
to measure the metabolism of DA. DA can be metabolized into 2 different products: 3-MT and 





C6 version of each metabolite can also be monitored. These metabolic measurements could 
prove useful for probing the effects of substances that alter DA turnover. 
SIL microdialysis can also be used to monitor small changes in the DA system otherwise 
unseen in uncalibrated microdialysis. For example, previous studies have shown that leptin 
increases DA uptake and TH activity, but has no effect on extracellular basal DA concentrations 
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in the NAc of rats fed ad-libitum when measured with uncalibrated microdialysis.
123, 163
 Using 
the increased accuracy afforded by SIL microdialysis, we sought to further examine the effects 
that leptin has on extracellular DA concentrations, uptake, and release in the NAc. 
Leptin conclusions 
Leptin is a hormone that is associated with food satiety with receptors present on 
dopaminergic neurons in multiple areas of the brain including the lateral hypothalamus, the 
ventral tegmental area, and the midbrain.
35
 Because leptin receptors are on DA neurons in areas 
of the brain associated with reward and feeding, studying the interaction between leptin and 
feeding can reveal a facet of the neurochemical cause of obesity. With SIL microdialysis, we 
were able to show that leptin (1 mg/kg i.p.) reduced the basal concentration of DA by 32 ± 5%. 
This effect was further investigated by a series of pharmacological studies. The decrease in DA 
concentration affected receptor occupancy because when the D2 antagonist raclopride was 
infused through the probe, the increase in DA was greater in vehicle treated rats vs. leptin treated 
rats. This result was interpreted as the effect of lower tone on D2 receptors with leptin causing 
lower release with raclopride. This effect was attributed to an increase in uptake. Indeed, our 
study was able to corroborate previous observations and further illustrate that uptake activity was 
greater with leptin. Extracellular DOPAC (produced in the neuron) concentrations increased 
more following the raclopride infusion in leptin treated rats vs. vehicle treated rats. The 
extracellular DOPAC increase could show that more DA is entering the neuron. The lower 
increase in extracellular DA and increase in DOPAC is indicative that leptin increased uptake. 
Monitoring the metabolites of DA with SIL microdialysis offers further insight into DA 
turnover with a leptin treatment. After leptin, the small increase in 
13
C6-DOPAC produced from 
13
C6-DA could be caused by more 
13
C6-DA being able to enter the neuron. While the endogenous 
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[3-MT]/[DA] ratio increased with leptin, the 
13
C6-3-MT produced from 
13
C6-DA was not 
affected by leptin. The increase in [3-MT]/[DA] was not due to an increase in COMT activity 
and may provide evidence of greater DA release. 
 Because previous studies had shown an increase in TH activity
123
 along with our 
observations of increased [3-MT]/[DA] ratio, we hypothesized that DA release might be 
increased. This effect was presumably masked in the basal concentration measurement by the 
increased DAT activity. To determine if increased DA release could be detected, cocaine and 
raclopride were infused through the probe. With uptake blocked, the DA in leptin treated rats 
increased more when compared to vehicle treated rats. The contribution of increased DA release 
seems to play a minor role compared to the increased uptake as these two opposing factors 
yielded a net decrease in basal DA. 
The increased DA uptake may be one of the processes used by leptin to decrease feeding. 
In a previous study, extracellular DA in the NAc increased more in vehicle treated vs. leptin 
treated food deprived rats when they received free access to food.
169
 Greater DA uptake may 
have been the cause for the attenuated increase. In a separate study, increasing DA in the NAc 
has been shown to increase the incentive salience of food.
161
 With leptin decreasing extracellular 
DA levels associated with feeding, the food becomes less rewarding. We propose that the 
modulation of DA by leptin through increased DAT activity is one of the mechanisms that leptin 
utilizes to promote food satiety. 
This thesis demonstrates the potential that SIL microdialysis has for making 
measurements in the central nervous system. The accuracy and information output is greater than 
uncalibrated microdialysis but requires the same amount of time and animals. The application of 
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SIL microdialysis should be pushed further to provide greater insight into the active processes 
and metabolic pathways that affect neurotransmitters other than DA and Glu. 
Future directions for SIL microdialysis 
 A useful direction for this work would be to evaluate how active processes in tissue 
modulate in vivo recovery by microdialysis. In previous studies of DA, the metabolism, 
synthesis, and release of DA were shown to have no effect on .
126
 Only changes in uptake 
affected . The rate of metabolism of DA is relatively slow compared to the uptake, which is 
why uptake controls  and decreasing metabolism does not.
126
 No studies like this have been 
performed with Glu. Glu is regulated differently than DA so inhibiting other processes like 
metabolism may affect . Glu is toxic at higher concentrations so the brain rapidly removes 
and metabolizes it. Inhibiting uptake of Glu decreases  but how metabolism of Glu affects Ed 
remains unknown. The Ed of other neurotransmitters, such as acetylcholine, may be controlled 
entirely by metabolism (acetylcholinesterase is the main method for clearing acetylcholine). By 
determining which tissue effects can control Ed, greater insight can be gained into how different 
pharmacological treatments affect neurotransmitter processing.  
Studying how different processes affect Ed can provide a method for determining the 
source of neurochemical changes. For example, when rats were given ethanol, an increase in 
 was measured in the hippocampus with no change in . The increased  was 
determined to be from increased release and not decreased uptake.
143
 Because the active 
processes that affect Ed in other neurotransmitters remain unknown, determining the source of 
increases and decreases in extracellular neurochemical concentrations remains challenging. 
Additionally, Ed may provide a tool for measuring possible drug efficacy. In a previous study, 






















































Glu. The amount of 
13
C5-GABA produced from the infusion 
of 5 µM [
13
C5-Glu]in was ~9000% higher than the 
13
C5-
GABA produced from 50 µM [
13
C5-Gln]in 
 was known to be dependent on the metabolism of Gln, the extent to which antiepileptic 
drugs affected  in the hippocampus might be correlated to the ability of the drug to reduce 
seizures. Characterization of SIL microdialysis using other neurotransmitters can lead to an 
understanding of which processes affect Ed for each neurotransmitter, which would provide 
measurements on tissue effects not observable with uncalibrated microdialysis. 




C5-Gln could be used to probe the source 
of 
13
C5-GABA in the brain. GABA neurons do not have the ability to form GABA from glucose 
so GABA is derived from Gln. The Gln enters the neuron, is converted to Glu, and is then 
converted to GABA by glutamate 
decarboxylase. In a preliminary 
experiment, we infused 50 µM 
13
C5-Gln through the probe and 
found that 0.10 ± 0.02 nM 
13
C5-
GABA was recovered by the 
probe. If 5 µM 
13
C5-Glu (Fig. 5.1) 
was infused through the probe, 






produced from 5 µM 13C5-Glu is 
9000% greater than from 50 µM 
13
C5-Gln, suggesting that extracellular Glu may play a larger role as a precursor to GABA than 
Gln. t Experiments testing TTX, Glu uptake inhibitors, and Glu decarboxylase inhibitors may 
shed light onto how GABA is synthesized. 
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 SIL microdialysis has been used to measure absolute concentrations, tissue effects, and 
metabolic flux. Our study of the effects of leptin on the DA system in the NAc can be expanded 
further into other areas of the brain. The measurements made in our study were downstream of 
leptin receptor containing neurons. Measuring the direct effect of leptin on the DA in the 
midbrain may yield additional information on feeding and obesity.  
Future directions for leptin study 
 In our study, a decrease in  was detected along with evidence for increases in uptake 
and release (most likely due to increase TH activity) in the NAc. With the use of benzoyl 
chloride and liquid chromatography coupled to a mass spectrometer, the sensitivity of our system 
is sufficient to measure DA with probes as small as 300 µm. This probe size is also acceptable 
for sampling from the lateral hypothalamus and the VTA, where leptin receptors are present. A 
future study could use SIL microdialysis to monitor how leptin alters the DA system in these 
areas. Leptin causes neuronal depolarization on DA neurons that contain leptin receptors.
36
 
Additionally, leptin has been shown to increase the amount of TH in both the VTA and NAc but 
not in the mediobasal hypothalamus of ob/ob mice after a leptin treatment.
163
 With the increased 
TH caused by leptin in the VTA, increased DA release should be observable after a leptin 
injection. DAT activity and changes in extracellular DA concentrations have not been measured 
in the VTA or the LH. Leptin may increase DAT activity in the LH and VTA, causing a decrease 
in extracellular DA. If not, an increase in the extracellular DA concentration in the VTA may be 
due to the increase in TH. Amphetamine and D2 antagonists could be injected or perfused 
through the probe to see the effect of leptin on these areas much like the studies performed in the 
NAc in this work and in other studies.
123, 169
 Monitoring the changes in the DA system can 
demonstrate the direct effects of leptin on brain areas that contain leptin receptors. 
90 
 
 Performing these measurements could provide insight into other mechanisms in which 
leptin regulates feeding. Microinjecting leptin directly into the VTA has been shown to decrease 
neuronal firing rates in anesthetized rats and decrease feeding in awake rats for up to 24 h.
157
 The 
VTA is a central site in the reward circuit in the brain. While our study provides evidence for 
changes in DA caused by leptin in the NAc, the mechanism of leptin regulating feed is not 
exclusive to the NAc. Measuring changes in the VTA and LH could provide additional 
information into obesity, rewarding effects of food, and how the interaction of leptin and DA 
play on each. 
Conclusion 
 The complexity and heterogeneity of the brain require analytical techniques with a high 
sensitivity, selectivity, and temporal resolution. This thesis provided a tool to improve upon 
microdialysis. With SIL neurotransmitters as a calibrant, microdialysis can be a quantitative 
technique that is able to indirectly measure tissue effects. SIL microdialysis also adds further 
information by providing a tool to measure metabolism. Monitoring SIL metabolites can provide 
information on enzymatic activity and can be used as an assay for measuring neuronal Glu 
release. No additional time is required for SIL microdialysis over uncalibrated microdialysis 
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